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1. Abstract 
Pneumonia caused by Streptococcus pneumoniae (S. pneumoniae) is worldwide an 
important healthcare concern amongst young, old and immunosuppressed patients. 
Alveolar macrophages (AMs) are the first line of defense, as they protect the lung 
from various pathogens and are crucial for the maintenance of lung homeostasis. 
The triggering receptor expressed on myeloid cells-2 (TREM-2) is a surface receptor, 
which is expressed on AMs and many other myeloid cells. Next to the role in bone 
formation and brain function, TREM-2 seems to be a negative regulator of immune 
responses. This is in contrast to a closely related receptor called TREM-1, which was 
shown to amplify immune responses. These contrasting effects are of special interest 
because both receptors require the DNAX activating protein of molecular mass 12 
kDA (DAP12) for signaling. Considering that Toll-like receptors (TLRs) as well as 
TREM-2 are constitutively expressed on lung mononuclear phagocytes and that 
these cells are crucial in the modulation of the inflammatory response upon infection, 
we hypothesize that TREM-2 plays an important role during bacterial pneumonia. 
In my work I show, that TREM-2 deficient AMs show enhanced phagocytosis of S. 
pneumoniae compared to wildtype cells. One possible explanation for this might be 
elevated Phosphatidylinositol 3 kinase (PI3-Kinase) activity, as well as increased 
ERK activity in the TREM-2 knockout cells. Furthermore I show evidence for the role 
of TREM-2 in the regulation of the actin cytoskeleton as well as for the regulatory 
function of TREM-2 in cytokine production.  
Another aspect of my diploma project was the identification of interactors 
downstream of TREM-2 or TREM-2/DAP12. We for this purpose decided to perform 
pulldown experiments and it was my task to make a TREM-2/DAP12 fusion construct 
and to generate stably transfected cell lines, expressing N-terminal tagged TREM-1, 
TREM-2 or the chimeric construct. The respective data are presented in this thesis. 
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2. Zusammenfassung 
Pneumonie, meistens verursacht durch Streptococcus pneumoniae, ist ein weltweites 
Gesundheitsproblem und betrifft alle Altersgruppen sowie immunsupprimierte 
Patienten. Alveolarmacrophagen (AMs) sind die wichtigsten Zellen des angeborenen 
Immunsystems der Lunge in frühen Phasen einer Infektion und außerdem notwendig 
für die Erhaltung des homöostatischen Gleichgewichts. Triggering receptor 
expressed on myeloid cells-2 (TREM-2) ist ein Oberflächenezeptor der von AMs und 
anderen myeloischen Zellen exprimiert wird. Neben seiner Rolle in Knochenbildung 
und Gehirnfunktion, ist TREM-2 ein wichtiger Negativregulator von Immunantworten, 
im Gegensatz zu dem nahe verwandten Rezeptor TREM-1, einem Verstärker von 
Entzündungsreaktionen. Dieser Kontrast ist interessant, da beide Rezeptoren mit 
dem gleichen Adaptorprotein, DAP12, assoziieren. Da TLRs sowie TREM-2 
konstitutiv von mononuklearen Phagozyten der Lunge exprimiert werden und 
essentielle Faktoren für die Modulation von Entzündungsreaktionen sind, gehen wir 
davon aus, dass TREM-2 eine wichtige Rolle in der Pathogenese einer bakteriellen 
Pneumonie spielt.  
In dieser Arbeit verifiziere ich, dass TREM-2-/- AMs eine verstärkte phagozytische 
Aktivität haben, wenn sie mit S. pneumoniae. stimuliert werden. Die Zellen zeigen 
außerdem eine erhöhte PI3-Kinase Aktivität sowie erhöhte ERK Aktivität. Weiters gibt 
meine Arbeit Hinweise auf eine regulatorische Funktion von TREM-2 für die 
Organisation des Aktin-Zytoskeletts sowie für die Cytokinproduktion. Der Fokus 
dieser Arbeit lag auf der Herstellung eines TREM-2/DAP12 Fusionskonstrukts und 
der Generation von stabil transfizierten Zelllinien, die N-terminal getaggte TREM-1, 
TREM-2 oder das Fusionskonstrukte exprimieren. Das Ziel war ein Pulldown 
Experiment um mögliche intrazelluläre Interaktionspartner von TREM-2 zu 
identifizieren. 
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3. Diplomathesis and research question 
Since function and downstream signaling of TREM-2 is not well understood, the aim 
of this diploma was, to further investigate the role of TREM-2 in pneumococcal 
infection, with a special focus on the signal transduction mediated by TREM-2. One 
approach was to compare the response of AMs from WT and TREM-2 deficient mice, 
upon stimulation with S. pneumonia and Lipopolysaccharide (LPS) in order to find 
possible differences in the activation of several pathways. Since morphological 
changes of the actin cytoskeleton were observed in TREM-2 deficient DCs and 
osteoclasts, confocal analysis of WT and TREM-2-/- AMs was performed. 
Another aim was to elucidate DAP12 dependent downstream signaling pathways 
induced via TREM-2 and to find novel interaction partners of TREM-2/DAP12 as well 
as possible downstream mediators of the TREM-2/DAP12 signaling complex upon 
stimulation with S. pneumoniae.  
To answer this question the idea was to produce stable TREM-2 transfected cell lines 
and perform a pulldown in Flp-InTM T-RExTM HEK 293 cells, by using a Streptavidin-
Hemaglutinin-tag (SH-tag), as well as in RAW 264.7 macrophages, using a Tandem 
affinity purification system with a tag consisting of Protein G coupled to streptavidin 
binding protein (GS-tag). The pulldown in HEK cells was performed because they are 
easy to transfect and the construct is not overexpressed, because it is inserted in the 
HEK cell genome just once. The pulldown in the in RAW cells has the disadvantage 
that transfection of these cells is not so easy and a retroviral transfection method has 
to be used, causing random insertion and overexpression of the constructs. Despite 
this a TREM-2 pulldown in RAW cells is of special interest, because of the possibility 
to study differences in complex formation when the cells are stimulated with S. 
pneumoniae. This is not possible in HEK cells because they do not express TLRs 
and therefore do not respond to the stimulus.  
Because the intracellular domain of TREM-2 is quite small, the proteins were tagged 
on the the N-terminus. Another problem is that many components of the TREM-
2/DAP12 complex might only bind to TREM-2 associated DAP12 and might not get 
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pulled down with TREM-2. To overcome this problem I generated a TREM-2/DAP12 
chimeric construct, which consists of the extracellular domain of TREM-2, fused to 
the intracellular domain of DAP12. Since there might be the possibility that the 
transmembrane part of DAP12 can pair with other receptors, like e.g. TREM-1, 
dectin-1, FcyR and thereby falsify results, I also generated a construct in which I 
introduced a mutation in the transmembrane (TM) domain of the chimera (TM-mutant 
chimera) that inhibits pairing with competing receptors (Fig. 1). 
 
Fig.1: Pulldown constructs and controls: TREM-2, TREM-2/DAP12 chimera (Chimera), 
transmembrane mutant TREM-2/DAP12 chimera (TM-mutant chimera)  
This approach might help to find possible adaptors, other than DAP12 which should 
interact with TREM-2 within the membrane, as well as binding partners of the small 
cytoplasmic domain of TREM-2. The TM-mutant of the TREM-2/DAP12 chimera 
functions as an important control and could pulldown proteins which interact 
specifically with the TREM-2/DAP12 complex, other controls will be TREM-1 as well 
as the exogenous protein GFP, which should allow to identify unspecific binding 
partners. By comparing pulldowns of stimulated and unstimulated cells this study 
should help to get insights into the function of TREM-2 upon infection. 
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4. Introduction 
4.1. Innate immunity and inflammation of the lung 
The mammalian immune system can be viewed as consisting of 3 different levels, 
anatomic and physiological barriers, the innate immune system and the adaptive 
immune system (Fig. 2) [1]. 
 
Fig.2: Integrated human immune system (modified from Turvey and Broide 2010) [1] 
 
The adaptive immune system is mediated by T- and B-Lymphocytes which are able 
to randomly generate a massive repertoire of antigen receptors against small and 
highly specific structures, called epitopes [2]. In contrast to the adaptive immune 
system, the innate immune system relies on a limited, germ line encoded repertoire 
of receptors, targeting conserved microbial structures that are shared by whole 
groups of pathogens and is mediated by cells of both hematopoietic and non-
hematopoietic origin [3, 4]. The innate immune system is very fast. It reacts within 
minutes after antigen exposure and starts to generate an inflammatory response. In 
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parallel with this initial inflammatory response, it is the innate immune system that 
activates and tailors the subsequent adaptive immune response [1]. 
The function of the lung is to supply the body with oxygen and to release carbon 
dioxide. This happens in the lung alveoli, which are made up of small type-I alveolar 
epithelial cells (AECs) on the surface and the more cuboidal type-II AECs, which are 
necessary for the production of surfactant and have self-renewal and differentiation 
potential. Since the inhaled air contains many particles including potential pathogenic 
microorganisms, the large surface of the lung also works as a “filter”. Lung capillaries 
are close to type I AECs to allow a proper gas exchange, but because of this 
proximity the lung is also an entrance point for many pathogens to enter the 
bloodstream, where they could cause a systemic infection. To avoid permanent 
inflammation, the immune system of the lung has to be highly regulated [5, 6].  
The lung is protected from potential harmful microorganisms by nonspecific and 
specific defense mechanisms. The resident immune system of the lung includes 
mucociliary clearance, antimicrobial proteins in the airway surface liquid and 
populations of myeloid cells. These cells function as sentinels and they are well 
equipped with pattern recognition receptors, strategically located in the lung tissue to 
encounter microbes in the air space [1]. The outcome of a pulmonary tract infection is 
dependent on two factors, the pathogen and the ability of the host to fight the 
infection, by eliciting an effective immune response. Small numbers of microbes 
might be cleared by the resident immune system, but numerous microbes or a higher 
virulent strain cause an inflammatory response [1]. 
Resident alveolar macrophages (AM) have been shown to be the first line of cellular 
defense and they are very important in the early phases of an infection. They are 
crucial for the maintenance of lung homeostasis and the modulation of the immune 
response [1, 7]. Only when the nonspecific mechanisms fail to eliminate a pathogen, 
pulmonary dendritic cells (DC) get activated and elicit an adaptive immune response. 
Next their key role in activating the adaptive immune response, DCs also have an 
important innate immune function in the response to viruses, by producing high levels 
of type-I-interferons [8].  
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In case of a serious infection, these early events lead to the recruitment of 
neutrophils, the major effector cells of innate immunity. They migrate out of the 
pulmonary capillaries and accumulate in the air spaces. After phagocytosis, 
neutrophils kill the ingested microbe with reactive oxygen species (ROI, NO), 
antimicrobial proteins and proteases [7, 8]. 
Lung inflammation can cause tissue damage and seriously harm the host. Thus, to 
better understand the interactions between host and pathogen during pneumococcal 
pneumonia, it is crucial to further investigate the mechanisms, which are determining 
the intensity of an inflammatory response in the lung. 
To sum up, inflammation always has two faces and it is of particular importance that 
inflammatory responses are highly regulated in the lung. A weak inflammatory 
reaction might not clear the host from a pathogen, whereas overwhelming 
inflammation directly contributes to the damage of cells and tissues. Thus lung injury 
and pulmonary dysfunction during infection are the result of a harmful interaction 
between the host and the pathogenic species [1, 6]. 
 
4.1.1. Pathogen recognition by the innate immune system 
As mentioned above, macrophages and all other cells of the innate immune system 
recognize infectious and endogenous ligands via so called pattern-recognition 
receptors (PRRs). PRRs are germ line encoded receptors, which bind to highly 
conserved molecular structures, known as pathogen-associated molecular patterns 
(PAMPs) [3, 4]. When PRRs get ligated, they trigger the release of proinflammatory 
cytokines, like tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), interleukin-1β and 
type I interferons (IFNs)[9] and induce the activation of the adaptive immune 
response[10]. 
Today, many different classes of PRRs are known to be important for the immune 
response. These are the Toll-like receptors (TLRs), Retinoic acid-inducible gene 
(RIG)-I-like receptors (RLRs) or the Nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLRs) [11]. 
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Twelve members of the TLR family have so far been identified in mammals, and the 
ligands for 11 TLRs are known. TLRs are glycosylated type I integral membrane 
proteins which form homodimers, like TLR3-TLR3, or heterodimers, like TLR1-TLR2 
or TLR2-TLR6. Signal transduction occurs upon ligation via their cytosolic Toll/IL-1 
receptor-like domain (TIR). TLR signaling leads to the activation of the nuclear factor 
κB (NFκB), the interferon regulatory factors (IRF) and other transcription factors, 
which ultimately results in the production of proinflammatory cytokines and other 
immunologic responses, like the maturation of DCs  (Fig. 3) [1]. NFκB proteins (also 
called Rel transcription factors) play key roles in the regulation of the innate as well 
as of the adaptive immune response. Under normal conditions they are located in the 
cytoplasm in association with inhibitory proteins called the inhibitors of NFκB (IκB). 
Upon stimulation of a cell, IκBs get phosphorylated, which is followed by proteasomal 
degradation.  Thereby NFκB is released and can translocate to the nucleus, where it 
binds to the DNA and activates various genes [12]. Some TLRs are expressed on the 
cell surface (TLR1, 2, 4, 5, 6), while others are expressed intracellular in endosomal 
compartments, like the endoplasmatic reticulum (ER) or endosomes (TLR3, 7, 8, 9). 
For a complete overview about TLRs, their localization and their ligands see Kumar 
2009 [11]. 
 
Fig.3: MyD88- and TRIF-dependent pathways in TLR signaling (modified from Akira 2009) [13] 
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Another PRR on phagocytes is the C-type lectin family member dectin1. Dectin1 is a 
transmembrane receptor with an important role in antifungal immunity, which can 
recognize the polysaccharide β-glucan that is part of the fungal cell wall.  Upon 
stimulation, the immunoreceptor tyrosine-based activation motif (ITAM) of dectin1 
gets phosphorylated and recruits the protein tyrosin kinase Syk, which then activates 
a signaling pathway involving CARD9, Bcl-10 and MALT1 [14, 15]. 
Nod-like receptors (NLRs) are a large family of about 20 proteins, which have diverse 
functions mediated by their N-terminal domain. All NLRs contain a nucleotide-binding 
oligomerization domain (NOD) and can be categorized in three subfamilies 
depending on their N-terminal domain. This domain is either a caspase-recruitment 
domain (CARD), in members of the NOD subfamily, a pyrin domain in the NALP 
subfamily (proteins containing a NACHT domain, leucine rich repeats and a pyrine 
domain) or a baculoviral-inhibitor-of-apoptosis-protein-repeat-containing (BIR) 
domain, in the NAIP (neuronal apoptosis inhibitory protein) subfamily [16, 17]. 
Members of the NOD subfamily, NOD-1 and NOD-2 are involved in the recognition of 
bacterial peptidoglycans and can trigger the production of cytokines and chemokines 
as well as the recruitment of neutrophils to the site of infection [17]. It has also been 
shown that they are important for the initiation of the adaptive immune response [18]. 
The NALP and the NAIP subfamilies are important for the production of IL-1 family 
members, like IL-1β. These cytokines are produced as inactive precursor molecules 
that need to be cleaved by caspase 1. In contrast to other cytokines, which require 
only TLR activation, IL-1 release therefore requires a second signal, which results in 
the activation of the inflammasome. Inflammasomes are large protein complexes, 
categorized according to their composition (NALP or NAIP), which are able to induce 
cleavage of pro-caspase 1, which in turn leads to processing of IL-1 precursor 
proteins [17, 19, 20]. 
Two types of cytosolic PRRs are known to be responsible for the recognition of viral 
nucleic acids. RIG-I and MDA5 are sensing viral RNA, whereas viral DNA is 
recognized by a protein called DAI [3, 17]. Since nucleic acid sensing PRRs are not 
of interest for the topic of this thesis and it would exceed the frame of this work, for 
more details see ref. 3 and 13. 
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4.1.2. Pneumonia 
As a major cause of death worldwide and the 6th common cause of death in the 
United States, pneumonia is a serious, persistent and widespread public health 
problem. Community-acquired pneumonia (CAP) is the single most prevalent 
infectious disease in the world and is defined as pneumonia acquired outside of a 
hospital [8, 21, 22]. CAP can be caused by a variety of pathogens including gram-
positive and gram-negative bacteria, viruses as well as fungi or protozoa. However, 
the single most frequent cause of CAP worldwide is based on an infection with S. 
pneumoniae [22].  
Because of the high mortality of CAP and the growing problem of bacterial resistance 
to many commonly used antibiotics [22], research in this field is of great medical and 
also social interest. Since the outcome of any infection depends on the virulence of 
the organism and the immune response of the host it is necessary to further 
understand the molecular interactions between the invading microbe and the immune 
system of the host during the manifestation of disease. 
 
4.1.2.1. Streptococcus pneumoniae 
S: pneumoniae is a gram-positive bacterium and one of the most important human 
pathogens. It colonizes the human nasopharynx and is the most frequent cause of 
pneumonia but can also lead to meningitis or otitis media. A vaccine against 
pneumococci is available, but it is not protective against all serotypes and is not very 
efficient for very young individuals and older people [23]. Similar to other pathogens, 
the virulence of S. pneumoniae strains depends on the expression of various 
virulence factors, which are either specific escape mechanism to evade from the host 
immune recognition or toxins, which are directly harming the host.  
The most important virulence factor is the polysaccharide capsule of S. pneumoniae 
with its strong antiphagocytic activity. The capsule shields the bacterial surface from 
binding of the complement component C3i and immunoglobulines. Thereby it 
prevents the interaction with corresponding Fc or complement receptors on 
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phagocytic cells and hence inhibits phagocytosis [24]. Furthermore, the 
polysaccharide capsule also enhances colonization, restricts autolysis, protects the 
pneumococcus against antibiotics [25] and significantly reduces trapping of the 
microbe within neutrophil extracellular traps [26]. 
The best studied pneumococcal virulence factor is the toxin pneumolysin (Ply), which 
has at least two biological activities, a lytic activity, by pore formation and the ability 
to activate the complement system of the host [23, 27]. 
Other virulence factors are LPXTG-anchored proteins, like hyaluronidase, 
neuraminidase or the serine protease PrtA. Important for the ability of S. pneumonia 
to colonize the human mucosa are several adhesive properties, which include pili and 
different lipoproteins. Choline-binding proteins (CBPs) are necessary for autolysis 
and thereby enhance the release of highly inflammatory cell wall degradation 
products as well as the release of pneumolysin. The pneumococcus also produces 
peptidoglycan modifying enzymes, making the pneumococcal peptidoglycan resistant 
to human lysozyme [25, 28], and expresses a DNAse, which protects the bacteria 
from killing by neutrophils [26]. 
In this work, the capsulated, ply-positive serotype 3 strain ATCC 6303 was used for 
all experiments. 
 
4.1.2.2. Innate Immunity in pneumococcal pneumonia 
When a pneumococcus enters the lower respiratory tract, the bronchial and lung 
epithelium act as a mechanical barrier and epithelial cells as well as alveolar 
macrophages recognize the invader via their PRRs.  
It is known that TLRs are crucial for the host to fight an infection with S. pneumonia. 
Pneumococcal cell wall components, like lipoteichoic acid (LTA) [29] and 
peptidoglycan, are recognized by TLR2 [30, 31] while ply is detected by TLR4 [32] 
and TLR9 might be involved in sensing bacterial DNA, released after autolysis of 
pneumococci [33]. 
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TLR ligation by the pneumococcus induces signaling pathways, activating NFκB and 
the IRF family of transcription factors [8]. TLR2 is expressed on Type-II AECs and 
has been shown to be responsible for S.pneumoniae-induced activation of the NFκB 
proteins RelA and p50 in this celltype, which are required for proper cytokine 
production, neutrophil recruitment and killing of bacteria [34]. However, NFκB has not 
only proinflammatory properties. While the translocation of RelA to the nucleus 
induces the expression of chemokines and adhesion molecules that are required for 
neutrophil recruitment, nuclear translocation of p50 downregulates the expression of 
pro-inflammatory genes [35, 36]. Translocation of NFκB proteins in pneumonia is 
also induced by the early phase cytokines TNFα and IL-1 [12]. In a mouse model of 
pneumonia, TNF-α is one of the first cytokines which is found in the BAL fluid as well 
as in the tissue [7]. Although TNF-α is required to elicit a proper immune response, 
exaggerated expression can lead to overwhelming inflammation and subsequent 
lung injury, which increases the risk of septic shock and death. AMs are the main 
source of TNF-α and therefore, are important modulators of inflammation in 
pneumococcal pneumonia [30]. 
Although AMs are essential for phagocytosis during early phases of the disease, the 
most important phagocytic cells to clear the lung from bacteria and to limit bacterial 
dissemination are neutrophils [37]. The innate immune response not only recruits 
neutrophils to the lung, it also increases neutrophil generation in the bone marrow 
and shortens their maturation time. The cytokines TNF-α and IL-1 induce the 
expression of the chemokine IL-8 (corresponding to KC in mice), which is a crucial 
factor for neutrophil chemotaxis [7]. After neutrophils phagocytosed bacteria, they 
rapidly undergo apoptotic cell death and are eliminated by AMs [37] 
Another important cytokine in pneumococcal pneumonia is IL-6. IL-6 increases the 
lifetime of neutrophils and enhances their cytotoxicity. Furthermore, IL-6  induces 
acute phase proteins such as C-reactive protein (CRP), and is involved in adaptive 
immune mechanisms [38]. The acute phase proteins CRP and mannose-binding 
lectin (MBL) are produced in the liver during pneumococcal pneumonia. They work 
as opsonins and enhance opsonized phagocytosis by neutrophils after binding to the 
bacterial surface [7, 39]. Together with the natural nonspecific immunoglobulin M 
(IgM), they activate the classical complement pathway [7]. 
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To prevent exaggerated tissue damage, the inflammatory process has to be tightly 
regulated. Two important anti-inflammatory, regulatory cytokines are working in 
concert to limit inflammation [40]. These are interleukin-10 (IL-10) and transforming 
growthfactor-β (TGFβ). IL-10 is crucial to reduce the production of proinflammatory 
mediators and can be produced by different subsets of helper- and regulatory T-cells, 
B-cells, granulocytes [41], neutrophils [42] as well as by AMs [5]. At baseline 
conditions TGF-β is expressed by AMs, counterbalances the activation of AMs and is 
therefore necessary to maintain lung homeostasis [5, 40]. 
 
4.2. Macrophages in innate immunity 
4.2.1. Macrophage development 
Macrophages are resident phagocytic cells found in lymphoid and basically all non-
lymphoid tissues. They are leukocytes and belong to the system of mononuclear 
phagocytes (together with dendritic cells and monocytes). Monocytes circulate in the 
blood and populate different tissues where they differentiate into macrophages. 
Macrophages show remarkable heterogeneity, depending on their specific function 
within the tissue (Fig. 4) [43].  
 
Fig.4: Monocyte heterogenity (modified from Mosser 2008) [44]  
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In the bone marrow hematopoietic stem cells (HMCs) produce myeloid progenitor 
cells (MP) and lymphoid progenitor cells (LP). The common MPs give rise to 
monocytes and many other cell types, including neutrophils, eosinophils, basophils,  
DCs and mast cells [44]. Monocytes can be proinflammatory and are the main source 
of inflammatory macrophages in tissues during an inflammatory process or trauma. 
Next to this, fully matured macrophages can also develop from tissue-resident 
colony-forming cells, like it is the case for microglia [43]. 
 
4.2.2. Macrophage function and polarization 
Macrophages are involved in immune responses, but they also have essential vital 
homeostatic roles. During an immune reaction they are crucial phagocytic, killing and 
antigen presenting cells and furthermore produce cytokines which are important to 
modulate the immune response. In a steady state situation macrophages are 
important in the removal of cellular debris during tissue remodeling and they clear the 
organism from apoptotic cells. In general, the receptors which are involved in these 
immune-cell independent processes fail to induce cytokine production or actively 
produce inhibitory signals [44]. 
When macrophages get activated, they can develop different functions and 
properties, depending on the stimulus. Endogenous stimuli are generated by innate 
immune cells, antigen-specific immune cells or from macrophages themselves. 
Exogenous stimuli are mostly PAMPs. In the past, macrophages have been classified 
into two groups, classically activated macrophages (M1) and alternatively activated 
macrophages (M2) [45]. Today it is known that there are much more types of 
macrophages and the term M2 has been changed to include all types of a 
macrophage, other than classic M1 [44, 46]. To get an overview, three major 
macrophage populations will be shortly mentioned in this work.  
Classic activation of macrophages happens due to stimulation with IFNγ, IFNβ or 
TNFα. In general, TLR agonists, like LPS, induce this phenotype, which is 
characterized by a high capacity to present antigen, produce proinflammatory 
cytokines (IL-12high) and to generate toxic intermediates (NO, ROI) [44, 46]. 
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Stimulation with IL-4 and/or IL-13 leads to the development of wound-healing 
macrophages. These M2 have an enhanced arginase activity, an enzyme that 
converts arginine to ornithine, which is a precursor of polyamines and collagen and 
thereby enhances the production of extracellular matrix. These macrophages 
produce only small amounts of proinflammatory cytokines and have decreased 
microbicidal activity, compared to classic M1 macrophages [45-47]. Regulatory 
macrophages are a sub-population of M2, which differentiate upon stimulation with 
glucocorticoids and/or immune complexes. These macrophages are characterized by 
a high production of the regulatory cytokine IL-10, very low expression of 
proinflammatory cytokines, a low capacity to present antigen and a low microbicidal 
activity. It is believed that their main function is to dampen an immune response and 
to limit inflammation [44, 47, 48]. 
 
4.2.3. Alveolar macrophages 
Alveolar macrophages are resident macrophages in the lung and are crucial to 
maintain lung homeostasis. Since AMs are continuously encountering inhaled 
substances, they have to be kept in a quiescent state to avoid tissue damage due to 
overwhelming inflammation. Thus, AMs have to be able to distinguish between 
harmless and potentially dangerous antigens and for a long time it was unknown 
which mechanisms are involved in the maintenance of lung homeostasis and which 
signals are required to induce an immune response.  
In steady state situations AMs produce low amounts of proinflammatory cytokines 
and show poor phagocytic activity. When they are mixed with DCs in vitro, they 
successfully suppress T-cell activation by producing IL-10, prostaglandins and TGF-
β[5]. Furthermore AMs actively suppress other innate and adaptive immune 
responses[49]. Under non-infectious conditions, AMs are in close contact with type-I 
and type-II AECs, which enable them to express the integrin αvβ6 that activates 
TGF-β. When AMs encounter danger signals like TLR ligands, they lose the close 
contact to the AECs and αvβ6 gets downregulated.  This leads to a loss of TGF-β 
inhibition, and AMs get activated, start to produce proinflammatory cytokines and 
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show enhanced phagocytic activity together with an increased killing efficiency. After 
a while the macrophages themselves reactivate TGF-β and go back to the steady 
state situation [50]. 
 
4.2.4. Phagocytosis 
Phagocytosis is defined as the actin dependent uptake of large particles (bigger than 
0.5µm diameter) by leukocytes and plays a very important role in the host defense 
against various invading microorganisms and the removal of apoptotic cells [51]. 
Two different receptor dependent mechanisms can mediate the internalization of 
particles by macrophages or neutrophils. On the one hand binding of a particle to a 
receptor can stimulate the extension of pseudopodia, which are then surrounding the 
particle and fuse at their tips. On the other hand a receptor can induce tight binding 
of the particle to the membrane, which is then displaced inwardly, by sinking the 
target into the phagocytic cell [52]. In both cases the particle ends up inside of the 
cell and gets processed in the so called phagosome, a membrane bound vacuole, 
which undergoes maturation. Maturation happens by finely tuned remodeling of the 
vacuole by fusion and fission with early and late endosomes as well as lysosomes. 
Especially late endosomes and lysosomes provide a lot of microbicidal components 
and contribute to the stepwise acidification of the phagosome, which finally results in 
the hybrid-organelle, called the phagolysosome. 
There are currently two alternative models, which try to explain how phagocytes can 
ingest large or multiple particles, without significant loss of cellular surface area. One 
hypothesis, the conventional model, postulates that the permanent fusion of 
endosomes with the plasmalemma keeps the surface area constant. The new 
hypothesis, the ER-mediated model, describes phagosome formation as a result of 
sliding of the particle into the endoplasmatic reticulum via an opening formed at the 
base of the phagocytic cup. In this case the ER provides most of the membrane to 
form the phagocytic vacuole, with maximal conservation of the surface membrane 
[53]. 
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4.2.5. Signaling in phagocytosis 
The initiation of the uptake of a particle and the activation of the phagocytosis 
machinery is triggered by multiple binding and clustering of phagocytic receptors. 
Today many phagocytic receptors on mammalian cells are known to be involved in 
the innate immune response. Examples for important receptors on macrophages are 
the different complement receptors (CRs), which bind to complement opsonized 
bacteria or fungi, the Mannose receptor, FcγRs, scavenger receptors like MARCO or 
CD36 and many others [54]. 
Activation of these receptors recruits members of the Src family, which either leads to 
phosphorylation of the receptors themselves, or to phosphorylation of 
immunoreceptor tyrosine-based motif (ITAM)-containing subunits [55]. The exact 
order of events after receptor activation is not clear. Phosphorylated ITAM then 
recruits the kinase Syk [56] and/or other kinases and the formation of the activated 
receptor complex involves recruitment of further adaptor molecules. Finally activation 
of the Phosphatidylinositol 3-kinase (PI3K) leads to lipid remodeling, by accumulation 
of 3´-phosphoinositides. Lipid remodeling is a highly regulated process and restricted 
in space and time, and at least partly controlled by the lipid phosphatase SHIP, which 
is also recruited to the phagocytic cup [57]. Phagocytosis leads also to an increased 
synthesis of phosphatidyinositol-4,5-bisphosphate (PIP2), which is a substrate of the 
PI3K but also of phospholipase C (PLC), which produces diacylglycerol (DAG). DAG 
in turn activates protein kinase C (PKC). In addition, other kinases like MEK1, ERK or 
the protein kinase A (PKA) have been shown to get activated upon phagocytosis 
[54]. This whole activation cascade goes hand in hand with cytoskeletal 
rearrangements, like the accumulation of F-actin and associated proteins in the 
periphagosomal region, which is mediated by different members of the Rho family of 
GTPases [58, 59] and leads to extension of pseudopodia. 
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4.3. Triggering receptor expressed on myeloid cells-2 (TREM-2) 
4.3.1. The TREM receptor family 
TREM proteins are a family of surface receptors, which mediate many different 
processes, like bone formation, neurological development and inflammation. The 
TREM cluster is located on the human chromosome 6p21 and on the mouse 
chromosome 17C3 and includes the genes encoding for TREM-1 and TREM-2 in 
both species, TREM-3, TREM-5 and a recently identified member PDC-TREM in 
mice, as well as genes encoding for the so called “TREM like” transcripts (TLTs) [60, 
61]. All members of the TREM family comprise single IgSF V-type domains. TREM-1, 
TREM-2 and TREM-3 do not contain any known motifs for signal transduction and 
signaling requires association with DAP12, an immunoreceptor tyrosine-based 
activating motif (ITAM) containing adaptor molecule. In contrast, some of the TLTs 
contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which have been 
shown to recruit the phosphatases SHP-1 and SHP-2 [62, 63]. 
Members of the TREM family are expressed on a variety of myeloid cells, where they 
mediate many diverse activating and inhibitory functions. The expression of TLT-2 on 
B- and T-lyphocytes is the only reported case of expression in the lymphoid lineage 
of cells [61]. One important feature of the TREM family is the ability to release soluble 
forms. Today soluble TREM-1, TREM-2 and TLT-1 have been detected in biological 
fluids of humans and animals suffering from infections [61].It is not known now how 
these soluble receptors are generated, there is evidence for alternative splicing, but 
also for metalloproteases which cut the membranebound form [61]. 
TREM-2 is an orphan receptor, expressed on myeloid cells as well as on non-myeloid 
cells[64]. Like other TREM family members the extracellular part of TREM-2 
comprises an IgSF V-type domain. It has a short cytoplasmic tail, a single pass, 
positively charged transmembrane (TM) domain and does not contain any known 
motifs for signal transduction [60]. Although a crystal structure for TREM-1 has been 
determined at 1.47Å [65], 1.76Å [66] and at 2.6Å [67] resolution, the chrystal 
structure of TREM-2 is still unknown. 
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4.3.2. Activating and inhibitory functions of DAP12 
To investigate TREM-2 signaling it is necessary to better understand the signal 
transduction mediated by its adaptor protein DAP12. Inside of a cell, downstream 
signals from many different receptors are overlapping and interacting in either a 
synergistic or an antagonistic way. Synergistic pathways are necessary to maintain 
the system sensitive to several stimuli, which individually would not reach the 
threshold to elicit cell activation. Antagonistic pathways are crucial to increase the 
specificity of a response by limiting activation in the presence of inhibitory signals 
[68].  
It is well known, that surface receptors with diverse functions associate with ITAM-
containing adaptor proteins like DAP12 or FcRγ. DAP12, also known as TYROBP or 
KARAP, seems to play a key role in signal integration within a cell. DAP12 was first 
described to mediate NK-cell activation via association with the killer-cell 
immunoglobulin like receptor (KIR) family and since this time many more cell surface 
receptors have been found to require pairing with DAP12 for signal transduction, like 
the Ly49 family on NK-cells and some T-cells, MDL1 on myeloid cells and many 
others. Also many members of the TREM family signal via DAP12 [68]. For a more 
detailed list of DAP12 associated receptors see Lanier 2009 or Turnbull 2007 (Fig. 5) 
[68, 69]. 
 
Fig.5: positively and negatively charged residues within the transmembrane domains of DAP10, 
DAP12, FcRγ and their associated receptors (modified from Lanier 2009) [69] 
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DAP12 is a short peptide with a length of only 113-114 amino acids, that has a 
minimal extracellular region (13-17 amino acids), a single pass transmembrane 
domain and a cytoplasmic domain, which comprises an ITAM [68], a conserved 
signaling element, which is defined as the following sequence D/ExxYxxL/Ix6-8YxxL/I 
[69].  
It has been shown that DAP12 interacts with associated receptors within the 
transmembrane domain via aspartic acids, which are centrally located within the TM-
domain of DAP12. Thus, the location of positively charged residues like lysine or 
arginine is critical for a receptor to pair with DAP12 and TREM-2 contains such a 
Lysin (Fig.4) [70]. 
Although DAP12 was first found as a mediator for cellular activation, over the last 
years inhibitory functions have been shown to be mediated by DAP12 as well [69, 71, 
72]. 
 
4.3.2.1. The ambiguity of ITAM signaling 
To understand the ambiguous character of DAP12 it is necessary to explain more 
about ITAMs and ITIMs. Based on their names, it was long believed that ITAMs 
always mediate activation, while ITIMs mediate cellular inhibition. Confusingly, further 
research identified ITAMs to exert inhibitory functions and ITIMs to mediate activating 
functions [73]. 
Upon ligation of any DAP12-associated receptor, Src family kinases get activated 
which then phosphorylate tyrosin residues within the ITAM of DAP12. Dual 
phosphorylated ITAMs serve as docking sites for the tandem SH2-domains of Syk 
kinases (Syk and/or Zap70), leading to phosphorylation of various substrates and 
subsequent cellular activation [68]. Inhibitory DAP12 signaling is less well 
understood. ITIMs contain the consensus sequence S/I/V/LxYxxI/V/L and upon 
phosphorylation they can recruit phosphotyrosine phosphatases (PTPs) like SHP-1, 
SHP-2 or the inositolphosphatase SHIP. Recruitment of these phosphatases results 
in reduced phosphorylation and therefore inhibition of activation pathway effectors. 
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Interestingly, DAP12 contains such an ITIM sequence within its ITAM, but it is 
unknown if it can recruit inhibitory phosphatases [73].  
A working model has been developed by Barrow et al., as an attempt to explain the 
polarity of DAP12-ITAM signaling: high avidity/affinity ligation of the DAP12-
associated receptor leads to “strong”, dual phosphorylation of the ITAM and 
subsequently to cellular activation, while binding of the receptor by low avidity/affinity 
ligands leads to “weak” or just partial phosphorylation of the closet ITIM within the 
ITAM, resulting in the recruitment of inhibitory phosphatases [72-74]. 
 
4.3.3. Nasu-Hakola disease 
Mutations in TREM-2 or its adaptor protein DAP12 in humans leads to a disease 
called Nasu-Hakola disease, also called polycystic lipomembranous osteodysplasia 
with sklerosing leukoencephalopathy (PLOSL). PLOSL is a recessively inherited, 
systemic disease and was first reported separately by Nasu and Hakola in the 1970s 
[75, 76]. PLOSL is a very rare, and characterized by progressive dementia and 
multiple cyst like lesions in the bones [77].  
The clinical course of PLOSL can be divided into 4 different stages: 1) a latent, 
symptom free stage, 2) an osseous stage, which is characterized by pain and mild 
swelling of ankles and feet, and bone fractures 3) an early neurological stage, when 
patients show first abnormalities of the central nervous system, manifested by 
personality changes and behavioral alterations and, 4) a late neurological stage, 
when patients suffer from fully developed dementia and are usually bedridden [77]. 
Onset of the disease is at an age around 20 +/- 10years and the patients usually die 
in the 4th to 5th life decade. Time between first clinical symptoms and death can vary 
between 3 and 35 years; purely neurological cases without bone lesions have been 
reported [78]. 
Genetic analyses of Finnish, Japanese and Brazilian patients showed that most of 
patients are homozygous for mutations in the DAP12 gene, which most likely lead to 
the absence or at least to the production of nonfunctional DAP12. The smaller group 
of patients with PLOSL has a fully functional DAP12 gene, but shows homozygous 
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loss of function mutations in the gene encoding for the DAP12-associated receptor 
TREM-2. All patients with PLOSL tested so far displayed a loss of function in 
DAP12/TREM-2 signaling [77]. Although DAP12/TREM-2 signaling seems to have an 
important immunologic function, there are no reports of an abnormally higher rate of 
infections or neoplasias among PLOSL patients.  
The fact that DAP12 is an adaptor molecule for many other receptors would assume 
loss of function of all DAP12-associated receptors in case of a nonfunctional DAP12. 
However in vitro immunological studies could not show any malfunctions of receptors 
other than TREM-2 [79]. These findings allow the following interesting conclusions: 1) 
PLOSL is caused by a loss of TREM-2 function in humans, 2) there might be 
compensatory mechanisms for DAP12-signaling, which can compensate for the loss 
of DAP12 in case of DAP12-associated receptors other than TREM-2 in human cells 
and 3) if there are compensatory mechanisms for the disrupted TREM-2/DAP12 
signaling pathway, this mechanism fails in the brain and in the bones [77]. 
 
4.3.4. TREM-2 expression and localization 
TREM-2 has been shown to be expressed on many different cells, like immature 
monocyte derived DCs, microglia, newly recruited peritoneal macrophages [80] and  
on alveolar macrophages upon induction [80, 81], bone marrow derived 
macrophages (BMDMs), hepatic macrophages and  endothelial cells. Furthermore 
TREM-2 is present on a variety of cell lines: THP-1 (monocytes), U937 (pre-
monocytes), CHME-5 and N9 (microglia), T98G and N2A (neuroblastoma), J774.2, 
IC21 and MT2 (macrophages), and RAW 264 (monocytes/macrophages) [64]. There 
is evidence from analysis of mRNA expression of in vitro differentiated DCs from 
different PLOSL patients (carrying loss of function mutations in either the TREM-2 or 
the DAP12 gene), that TREM-2 expression is down regulated in absence of DAP12, 
but DAP12 levels remain unaffected, when TREM-2 is missing [82], which is likely to 
be possible, since DAP12 associates also with receptors other than TREM-2. 
In the mouse brain TREM-2 and DAP12 expression is detectable already in the 
embryo on day 17. Interestingly the transcripts, as well as the proteins show co-
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localization with a microglial marker, indicating a function of TREM-2/DAP12 
signaling in brain immune function [83]. Since DAP12 is a very promiscuous protein 
and necessary for signal transduction of many different receptors other than TREM-2, 
it is obvious that DAP12 has to be expressed in higher levels than TREM-2, which 
has been shown for murine microglia and oligodendrocytes [84]. A soluble form of 
TREM-2 (sTREM-2) has been found in human cerebrospinal fluid and in serum and 
has been shown to be upregulated in patients with multiple sclerosis (MS) or other 
inflammatory neurologic diseases. Foamy macrophages in actively demyelinating 
MS-lesions express high levels of TREM-2 [85]. 
Confocal studies on microglial N9 cells showed TREM-2 on the cell surface, but also 
TREM-2 localization in two intracellular pools, the golgi cisternae and distributed as 
discrete puncta in the cytoplasma [86]. A small fraction of the puncta was colocalizing 
with markers for the trans-golgi network (TGN) and they were just rarely colocalizing 
with markers for endosomes and lysosomes, so the nature of the receptor positive 
organelle remained unknown. Stimulation with inonomycin, a Ca2+ inophore which 
induces large increase of the cytosolic Ca2+ concentration, induces an increase in the 
surface expression and the same is true for LPS stimulation, although the expression 
is increased much slower [86]. It was shown before in neurons and microglia of 
human and mice, as well as in human microglia and glioblastoma celllines, that 
TREM-2 is localized mostly within the cells, not at the surface [87]. In a mouse model 
for acute endotoxemia, TREM-2 expression is decreased on hepatic macrophages 
and endothelial cells from C3H/HeOuJ mice, in contrast to TREM-1 and TREM-3, 
which are increased [88]. 
In general TREM-2 expression might be a useful marker for macrophage 
development and/or activation, for example it has been shown that it is expressed on 
infiltrating, but not resident peritoneal macrophages. Furthermore TREM-2 is the 40th 
most highly induced gene in human smokers [80]. Expression is up-regulated in 
mouse AMs after chronic 2nd hand smoke exposures [81], during allergen induced 
pulmonary infection and there is evidence that TREM-2 levels increase during 
alternative activation of AMs, by stimulation with IL-4 and IL-13. In contrast TREM-2 
is down regulated in response to LPS or IFN-γ in AMs [80] and in response to IL-1β 
and TNFα in mouse hepatic macrophages and endothelial cells [88]. 
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4.3.5. Signaling and functions of TREM-2 
4.3.5.1.  Immunological aspects of TREM-2 signaling 
TREM-2 is an important factor in maintenance of immune system homeostasis [89] 
and in contrast to its relative TREM-1, which has been shown to amplify immune 
responses [90], TREM-2 rather seems to be a negative regulator. Compared to wild 
type cells, TREM-2-/- BMDMs produce more TNF-α in response to CpG, zymosan or 
LPS and also thioglycollate-recruited peritoneal macrophages produce more TNF-α 
and IL-6 in response to LPS [80]. DAP12-/- BMDMs have a similar phenotype and 
have shown higher TNF-α production, when stimulated with TLR-ligands like CpG, 
DNA or Zymosan. Cytokine production could be rescued by transfecting DAP-12-
deficient cells with DAP12, but a transmembrane mutant of DAP12 (TM-DAP12) 
failed to rescue cytokine levels, indicating that DAP12 requires the interaction with 
another receptor for its inhibitory function.  Full rescue of cytokine levels with a 
TREM-2/DAP12 chimera finally showed that pairing of DAP12 with TREM-2 was 
required for inhibitory DAP12 signaling [71]. 
There is strong evidence that TREM-2 is able to form higher order complexes. 
TREM-2 co-precipitates with DAP12 and Plexin-A1 in COS7 cells [91]. Plexin-A1 is a 
semaphorin receptor which has been shown to play an important role in bone 
formation and immune function. Similar like TREM-2, Plexin-A1 deficiency in mice 
results in increased bone mass and signs of osteopetrosis because of nonfunctional 
osteoclasts. Furthermore Plexin-A1-/- mice have DCs, which are poor in the 
stimulation of allogeneic T-cells and antigen specific T-cells [91] and there is other 
evidence that TREM-2 might play a role in the antigen uptake of DCs and in the 
retention of a matured stage [92]. 
The linker for activation of B-cells (LAB or NTAL) has been shown to be an important 
regulator for TREM-2 signaling, and thereby influences the inflammatory response of 
macrophages. LAB might suppress or antagonize TREM-2 signaling, so it is 
interesting that LAB deficient cells shift from IL-12p40 production to IL-10 production 
[93]. 
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Syk is recruited in macrophages to ITAMs in adaptor proteins after phosphorylation 
and it has been shown that DAP12 requires Syk for inhibitory downstream signaling. 
[72]. TREM-2, DAP12 and Syk have been shown to be crucial for the fusion of 
macrophages to multinucleated giant cells but do not affect macrophage 
development. DAP12 overexpression enhances fusion of macrophages stimulated by 
IL4 [94]. 
Additionally to its regulatory role in cytokine production, TREM-2 has also been 
identified as a phagocytic receptor [95]. DAP12 and TREM-2 defecient BMDMs show 
a decreased ability for phagocytosing bacteria and TREM-2 transfected Chinese 
hamster ovary (CHO) cells are able to internalize Pseudomonas aeruginosa, 
Francisella tularensis and Staphylococcus aureus. The phagocytic process has been 
shown to be dependent on Syk as well as on Rac1 and CdC42 [95].  
In our lab experiments with TREM-2 deficient BMDMs also showed that these cells 
have a decreased phagocytic activity compared to wild type (WT) cells, when 
challenged with E. coli or S. pneumoniae. Controversially, AMs from TREM-2 
deficient mice phagocytose more heat killed E. coli and S. pneumoniae than WT 
AMs. In an infection model of pneumococcal pneumonia with WT and TREM-2-/- 
mice, TREM-2 deficient mice showed an improved survival (unpublished data O. 
Sharif). 
 
4.3.5.2. TREM-2 and the brain 
As mentioned before, TREM-2 and DAP12 are co-expressed in the central nervous 
tissue and abundant in microglia of man and mice. It is already widely accepted that 
TREM-2 is necessary to maintain central nervous tissue immune homeostasis, 
evidenced by the fact that human mutations of TREM-2 or DAP12 result in early 
onset dementia and that TREM-2 on microglia has been shown to be involved in 
phagocytosis of apoptotic material [89]. Furthermore TREM-2 is sufficient to induce 
phagocytosis of apoptotic neuronal cells by CHO cells, which are usually non-
phagocytic [96]. 
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Since TREM-2 is involved in the dampening of inflammatory responses, it is not 
surprising, that there is an involvement of TREM-2 in experimental autoimmune 
encephalomyelitis (EAE), an animal model for multiple sclerosis.  
In a mouse model of EAE, TREM2 is upregulated in lymphnodes and spinal cord as 
well as on macrophages and microglia and that blocking of TREM-2 in the effector 
phase of EAE, worsens the disease [97]. 
 
4.3.5.3. TREM-2 and osteoclastogenesis 
DAP12-/- and TREM-2-/- monocytes, isolated from PLOSL patients show a delayed 
differentiation into osteoclasts [98]. Upon in vitro differentiation by stimulation with 
RANKL and M-CSF, the formation of polynucleated cells is strongly decreased in 
TREM-2-/- as well as in DAP12-/- cells compared to control cells from healthy 
donors. Furthermore, these osteoclasts have an aberrant morphology. Confocal 
analysis showed that these cells are smaller than control cells and show aberrant 
actin organization, a phenotype which was more pronounced in DAP12-/- cells as 
compared to TREM-2-/- cells. Defects in the bone resorption ability were also 
observed [98, 99]. Later, IL-10 was described to inhibit osteoclastogenesis by limiting 
TREM-2 expression on a transcriptional level and TREM-2 was found to be a 
regulator of RANK signaling [100]. 
 
4.3.5.1. TREM-2 and the cytoskeleton 
TREM-2 definitely plays a role in the organization of the cytoskeleton. Although 
DAP12 and TREM-2 deficient monocytes (isolated from PLOSL patients with either 
non-functional DAP12 or TREM-2) are able to differentiate in vitro into functional DCs 
and to respond to microbial stimuli, these DCs show alterations in their actin 
cytoskeleton [82]. They have a larger surface, due to an increased number of 
processes, compared to wild type DCs [82]. An effect of TREM-2/DAP12 signaling 
was also observed in osteoclasts as mentioned before, where a staining for F-actin 
with phalloidin showed granules of unorganized actin filaments [99]. 
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4.3.6. The mystery of the TREM-2 ligand 
Like for almost all members of the TREM family, a ligand for TREM-2 has not been 
identified yet. The only exception is TLT-2, which has been shown to bind the B7 
family member B7-H3 [101], an important costimulatory molecule for T-cells [102]. 
There is evidence for endogenous ligands on TREM-2 expressing cells. Hamerman 
et al. showed that a TREM-2/Fc chimera binds to the surface of peritoneal 
macrophages and BMDMs, indicating the expression of a membrane bound, 
endogenous ligand [72]. TREM-2-ligands have been found also on the surface of 
astrocytoma cells [103] and on neurons, activating a receptorcomplex upon ligation, 
which can be inhibited by the administration of a blocking TREM-2 antibody. The 
expression of these endogenous ligands was shown to be increased on neuronal and 
non neuronal apoptotic cells [96]. 
Other studies showed binding of TREM-2 to whole bacteria and to bacterial cell wall 
components. Experiments with a TREM2a/Ig fusion protein proved binding to a 
variety of gram positive and gram negative bacteria like S. aureus, E. coli, P. 
mirabilis, S. pyogenes. Only weak binding was observed to P. aeruginosa and S. 
xylosus and no binding at all to C. albicans. Binding of bacteria to TREM-2 
transfected cells could be blocked by sTREM-2 or by adding anionic bacterial 
products and other anionic carbohydrates, suggesting that TREM-2 has a high affinity 
for anionic ligands [103]. 
TREM-2 was also shown to bind to lipooligosacharide (LOS) of Neisseria 
gonorrhoeae, by far western blot and surface plasmon resonance, which also 
supports the hypothesis of binding preferentially anionic substances [104]. 
Another study identified the chaperone Hsp60 as an agonistic ligand for TREM-2 on 
microglia [105] and last but not least, the finding that TREM-2 associates with plexin-
A1 gives evidence for TREM-2 being involved in the formation of higher order 
receptor complexes [91]. When searching for a TREM-2 ligand one has to take into 
account that it is not known if a putative TREM-2 ligand would interact with TREM-2 
in such a complex or if TREM-2 would just function as orphan signaling component 
[61]. 
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5. Material and Methods 
5.1. Material 
5.1.1. Media and supplements 
Antibiotics:  Pen/Strep (GIBCO 15140, 10000U/ml Penicillin, 10000µg/ml 
Streptomycin) 
Puromycin (Sigma-Aldrich P-7255, 5mg/ml) 
Geniticin (GIBCO G-418, 50mg/ml)  
Blasticidin (Invitrogen R210-01, in H2O, 10mg/ml) 
Hygromycin (Invitrogen 10687-10, 50mg/ml)  
Doxicyclin (Sigma-Aldrich, D9891-5G, in 70% Ethanol, 2mg/ml)  
Ampicillin (Sigma-Aldrich A-9518, 10mg/ml)  
Kanamycin (GIBCO 15165, 10000 µg/ml)  
Additives: FCS (fetal bovine serum, GIBCO 10082-147) 
RAW media: RPMI 1640 (GIBCO 21875-034) for AMs and Dulbeccos modified 
eagle medium DMEM (GIBCO 31885-023) for RAW cells, 
supplemented with 10% FCS and 1% Pen/Strep 
HEK media: DMEM supplemented with 10% FCS and 1% Pen/Strep, for pSelect 
HEK cells also with 1% Puromycin and 1% Geniticin 
LB media: 10g NaCl, 10g Tryptone and 5g yeast extract filled up to 1L with 
ddH2O (Antibiotics were added after autoclaving) 
LB agar: 10g NaCl, 10g Tryptone, 5g yeast extract, 20g Agar filled up to 1L 
with ddH2O (Antibiotics added after autoclaving) 
TH media: (= THB, Todd Hewitt broth) prepared by Bianca Doninger  
(THB: 10g Infusion from 450 g fat-free minced meet, 20g Tryptone, 
2g Glucose, 2g Na2CO3, 2g NaCl, 0.4g Na2HSO4, for 1L: 36.4g THB 
in dissolved in ddH2O and autoclaved)    
Blood agar: Sheep blood agar plates (Biomérieux) 
SOC media: 2% Tryptone, 0.5% Yeast extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2, 10mM MgSO4 in ddH2O, 20mM sterile filtered Glucose added 
after autoclaving 
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5.1.2. Chemicals 
5.1.2.1. Buffers and Solutions 
Buffer Ingredients pH Application 
10xPBS Morphisto (1123700500) 7.4 westernblotting, cellculture 
10x TBE Buffer 
109g Tris, 55g Boric acid, 4.65g 
EDTA in 1l ddH2O 
(adjust to pH 8.0 with NaOH) 
8.3 Preparation of Agarose gels 
5x Raw detachment 
buffer (RdB) 15mM KAc, 150mM KCl in ddH2O n.a.* 
Detaching of 
RAW cells, 
splitting 
Paraformaldehyde 
3.7% solution 3.7% PFA in PBS n.a. 
Fixation of cells 
for confocal 
microscopy 
WCE Lysisbuffer  
20mM HEPES, 500mM NaCl, 1mM 
EDTA, 25% Glycerol, 0.1% NP40, 
1Mm DTT; 5mM NaF, 1mM Na-
Vanadate, 1mM PMSF, Aprotinin 
(Sigma, 1:1000) 
7.9 
Preparation of 
whole cell 
extracts 
NP-40 buffer 
150mM NaCl, 1% NP-40, 50mM 
Tris 
(inhibitors like WCE buffer) 
8.0 
RIPA buffer 
150mM NaCl, 1% NP-40, 0.5% Na-
Deoxycholate, 0.1% SDS, 50mM 
Tris 
(inhibitors like WCE buffer) 
8.0 
Chaps buffer 
150mM NaCl, 30mM Tris, 1% 
Chaps 
(inhibitors like WCE buffer) 
8.0 
Solution C 6.06g Tris, 0.4g SDS in 100ml ddH2O 
6.8 Preparation of 2x SDS SB 
2x SDS sample buffer 
(SB) 
12.5ml Solution C, 5ml β-
Mercaptoethanol, 10.1ml Glycerol 
(99%), 2g SDS, 5mg 
Bromphenoleblue in 50ml ddH2O 
n.a. 
Western blotting 
10x running buffer per [l]: 30.3g Trizma base, 150g Glycine, 10g SDS n.a. 
10x Semi-dry blotting 
buffer 
 48mM (=58g) Trizma base (Sigma; 
T-1258), 39mM (=29g) Glycine 
(Merck; 104201), 0.01% (=1g)  
SDS (Sigma; L-3771) in 1 ddH2O; 
 
Blocking solution 5% BSA or 5% milk powder in PBS n.a. 
Washing solution 
(PBST) PBS with 0.1% Tween-20 n.a. 
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Stripping buffer 200mM Glycine, 150mM NaCl, 0.01% Tween-20 in ddH2O 
2.5 
HNN-lysis buffer 
50mM HEPES, 5mM EDTA, 
150mM NaCl, 50mM NaF, 1mM 
PMSF, 1.5mM Na-Vanadate, 0.5% 
NP-40, protease inhibitors (Sigma 
P8340), 1µg/ml Avidin 
8.0 
Pulldown 
HNN-buffer 50mM HEPES, 5mM EDTA, 150mM NaCl, 50mM NaF 8.0 
* n.a. = not adjusted 
 
5.1.2.2. Reagents, Stimuli and Inhibitors 
Substance Company Application 
Saline Mayrhofer Pharmazeutika BAL 
Trypanblue Sigma-Aldrich T8154 Staining of dead cells 
Ethidiumbromide. Sigma-Aldrich 10mg/ml DNA gels 
Lidocain 
GebroPharma, Xylanest 
2% with Epinephrin 
(1:200000) 
detaching cells 
Bradford reagent Biorad Protein Assay 500-0006 protein concentration 
ProFluoprep bioMerieux Confocal microscopy 
Instant milk powder Maresi 
blocking Bovine serum albumine Fraction V, Roche 10735094001 
Alexa-Fluor Phalloidin Invitrogen A12379 Dyes for confocal 
microscopy DAPI Sigma 32670 Lysotracker Invitrogen MP07525 
Polyfect Quiagen 301105 Tranfections FuGene6TM Roche 11814443001 
Heat killed S. pneumonia 
(strain ATCC 6303) 
prepared by O. Sharif 
(supplementary protocol) 
Stimuli FITC labeled S. pneumoniae prepared by O. Sharif (supplementary protocol) 
LPS Sigma 
MG132 Biomol PI 102-0005 Proteasome inhibitor 
Strep Tactin sepharose IBA, 2-1201-010 beads Anti-HA agarose Sigma A2095 
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5.1.2.3. Kits 
DNA purification kit (GE Healthcare), MiniPrep/MaxiPrep Kits (Quiagen), Quick 
Change - site directed mutagenesis Kit (Stratagene), TNF ELISA (R&D Duoset, 
EY410), IL-6 ELISA (R&D Duoset, DY406), TMB Microwell Peroxidase Substrate 
System (KPL, 50-76-00) 
 
5.1.2.4. Antibodies 
Primary Antibodies 
Antibody Company Species Application Dilution 
anti mouse TREM-2 
R&D, APC-
conjugated FAB 
17291A 
Rat IgG 
2b FACS 1:10, 1:50 
IgG isotype control 
R&D, APC-
conjugated, 
IC013A 
Rat IgG 
2b 
FACS isotype 
control 1:50 
anti mouse TREM-2 
(G-16) 
Santa Cruz 
Sc-22634 goat 
Confocal 
microscopy 1:50 
Anti-Myc Tag, 
IRDye800® 
conjugated  
Rockland 
immunochemicals rabbit 
Western blotting 
1:7000 
Monoclonal anti-HA Sigma H6533 1VL mouse 1:5000 
Phospho-p44/42 
MAPK (ERK1/2) 
(Thr202/Tyr204) 
mAb 
Cell Signaling 
9106 mouse 
1:1000 
Phospho-p38 MAP 
kinase 
(Thr180/Tyr182) 
Cell Signaling 
9211 
rabbit 
Phospho-Akt 
(Thr308) mAb Cell Signaling 
Phospho-AKT 
sampler kit 9916 
Phospho-GSK-3β 
(Ser9) mAb 
Phospho-PTEN 
(Ser380) 
Secondary Antibodies 
Antibody Company Species Application Dilution 
anti-mouse IgG 
(H&L) Antibody 
IRDye700DX® 
conjugated 
Rockland rabbit Western blotting 1:20000 
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anti-rabbit IgG 
(H&L) Antibody 
IRDye700DX® 
conjugated 
goat 
IRDye 800CW anti 
rabbit, IRDye 
680CW anti mouse 
Licor Rabbit, goat 1:15000 
IgG-FITC conjugate Millipore AP180F Donkey anti goat Confocal 1:400 
 
 
5.1.3. Enzymes 
Enzyme Buffer Company 
Native Pfu DNA polymerase 10x Pfu buffer Stratagene, 2.5U/ml 
High Fidelity polymerase 10x HiFi buffer + 15mM MgCl2 
Fermentas, 5U/ml  
Klenow polymerase 10x NEBuffer 2 BioLabs, 5U/ml 
EcoRI 10x Buffer H Roche 11175084001 XhOI high conc. Roche 10703770001 
BamH1 fast digest 10x FD buffer Fermentas ER0054 PstI fast digest  
Shrimp alcaline phosphatase 10x AP buffer Fermentas EF0511 
T4 DNA ligase 10x ligation buffer Fermentas K1421 
 
 
5.1.4. Primers and Vectors 
5.1.4.1. Vectors 
mTREM-2 pORF, hTREM-2 pORF, hTREM-1 pORF (obtained from invivogen), 
mDAP12 sport6, hDAP12 sport6 (obtained from imagenes), hTREM-1, pIRES 
(obtained from Stratagene), pDONR201, pRVNTAP GS2xT Gw, pTO HA StrepIII GW 
FRT (Stratagene), VSV-G was kindly provided by Prof. Superti Furga. 
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5.1.4.2. Primers 
All primers were ordered from Sigma-Aldrich and diluted with nuclease free water up 
to a concentration of 100µM. 
species primer description Sequence 5´→ 3´ application 
mouse 
mP1 mTREM-2 forward ATGGGACCTCTCCACCAGTTTCTC 
step 1 
generation of 
overlapping TREM-2 
and DAP12 fragments 
 
step 3 
P1 and P4 were also 
used for the 
amplification of the 
fusion product 
 
 
mP2 mTREM-2 reverse + mDAP12 overhang 
AGTGTCACTCTGGGGTGGGAAGGAG
GTCTCTTGATT 
mP3 mDAP12 forward + mTREM2 overhang 
TCCTTCCCACCCCAGAGTGACACTT
TCCCAAGATGC 
mP4 mDAP12 reverse TCATCTGTAATATTGCCTCTGTGT 
human 
hP1 hTREM-2 forward ATGGAGCCTCTCCGGCTGCTCATC 
hP2 hTREM-2 reverse + hDAP12 overhang 
GCTCTGGGCCTGGGGTGGGAAGGGG
ATTTCTCCTTC 
mP3 hDAP12 forward + hTREM2 overhang 
CCCTTCCCACCCCAGGCCCAGAGCG
ATTGCAGTTGC 
mP4 hDAP12 reverse TCATTTGTAATACGGCCTCTGTGT 
mouse 
mP5 mChimera pIRES XHOI forward 
GCCTCGAGATGGGACCTCTCCACCA
GTTTCTC 
Cloning 
Introduction of restriction 
sites 
mP6 mChimera pIRES EcoRI reverse 
GCGAATTCTCATCTGTAATATTGCC
TCTGTGT 
human 
hP5 hChimera pIRES XHOI forward 
GCCTCGAGATGGAGCCTCTCCGGCT
GCTCATC 
hP6 hChimera pIRES EcoRI reverse 
GCGAATTCTCATTTGTAATACGGCC
TCTGTGT 
mouse 
mP7 Mutagenesis forward 
GGGATTGTTCTGGGTGCATTGGTGT
TGACTCTGCTG 
Site directed 
mutagenesis (Page 
purified primers) 
mP8 Mutagenesis reverse 
CAGCAGAGTCAACACCAATGCACCC
AGAACAATCCC 
human 
hP7.1 Mutagenesis forward 
GGGATCGTGATGGGAGCACTGGTGC
TGACAGTGCTC 
hP8.1 Mutagenesis reverse 
CCCTAGCACTACCCTCGTGACCACG
ACTGTCACGAG 
hP7.2 Mutagenesis forward 
GATCGTGATGGGAGCACTGGTGCTG
ACAGTGCTC 
hP8.2 Mutagenesis reverse 
GAGCACTGTCAGCACCAGTGCTCCC
ATCACGATC 
mouse 
mP9 N-Tap mTREM-2 sense attB1 
GGGGACAAGTTTGTACAAAAAAGCA
GGCTCCATGGGACCTCTCCACCAG 
Adding att-sites for 
Gateway cloning 
mP10 N-Tap mTREM-2 antisense attB1 
GGGGACCACTTTGTACAAGAAAGCT
GGGTTCACGTACCTCCGGGTCC 
mP11 N-Tap mDAP12 antisense attB1 
GGGGACCACTTTGTACAAGAAAGCT
GGGTTCATCTGTAATATTGCCT 
human 
hP9 N-Tap hTREM-2 sense attB1 
GGGGACAAGTTTGTACAAAAAAGCA
GGCTCCATGGAGCCTCTCCGGCTG 
hP10 N-Tap hTREM-2 antisense attB1 
GGGGACCACTTTGTACAAGAAAGCT
GGGTTCACGTGTCTCTCAGCCC 
hP11 N-Tap hDAP12 antisense attB1 
GGGGACCACTTTGTACAAGAAAGCT
GGGTTCATTTGTAATACGGCCT 
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hP12 N-Tap hTREM-1 sense attB1 
GGGGACAAGTTTGTACAAAAAAGCA
GGCTCCATGAGGAAGACCAGGCTC 
hP13 N-Tap hTREM-1 antisense attB1 
GGGGACCACTTTGTACAAGAAAGCT
GGGTCTAGGGTACAAATGACCT 
 
 
5.1.5. Instruments 
Hitachi U2000 spectrophotometer, Licor Odyssey infrared imaging system, Zeiss 
Confocal microscope LSM510, PCR Express Hybaid Thermocycler, Biorad UV 
universal hood (Gel visualization) 
 
5.2. Methods 
5.2.1. Cell culture 
5.2.1.1. Alveolar Macrophages (AM) 
Wildtype and TREM-2 -/- mice were euthanized with isoflurane and primary AMs 
were harvested by bronchoalveolar lavage (BAL). BAL fluid was centrifuged 
(1250rpm, 7min, RT, Rotanta 460R Hettich centrifuges) and the pellet resuspended 
in 1ml RAW media.  Cells were counted in a counting chamber with trypanblue (1:1 
dilution) to check for viability, plated in RAW media and adhered at 37°C over night.  
Subsequently, they were washed twice with PBS to remove erythrocytes and left to 
rest at 37°C at least 3h before stimulation.  
 
5.2.1.2. RAW 264.7 cells 
RAW 264.7 cells were cultured in RAW media and split three times per week at a 
ratio of 1:10.  Cells were washed with PBS and detached by adding 1ml of 1x RAW 
detachment buffer (Rdb). 
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5.2.1.3. HEK cells 
All HEK cells were split three times per week at a ratio of 1:6 by washing once with 
PBS and detaching using PBS supplemented with 2mM EDTA. 
 
5.2.2. Production of a TREM-2/DAP12 fusion construct 
5.2.2.1. Generation of a TREM-2/DAP12 chimera by PCR 
A TREM-2/DAP12 chimeric construct consisting of the extracellular domain of TREM-
2 (aminoacids 1-169) fused to the transmembrane and intracellular domain of DAP12 
(aminoacids 28-114), was generated by a 3 step overlap extension PCR. The method 
was adapted from Wurch et al. [106] and this chimera was already generated before 
by Hamerman et al. and shown to be functional in dampening cytokine responses 
[71]. 
In step1, fragments with overlapping regions were generated by PCR (primers: P1, 
P2, P3, P4), separated and purified with a DNA purification kit after gel 
electrophoresis (2% agarose gel 100µg/ml Ethidiumbromide).  
PCR – mix 1: 
Fragment mDAP12 mTREM2 hDAP12 hTREM2 
H2O 
[µl] 
75.3 75.3 75.3 75.3 
10 x Pfu buffer 10 10 10 10 
dNTPs [10µM] 2 2 2 2 
Template [~2000ng/µl] 10 10 10 10 
mP1 or hP1 [100µM] - 0.4 - 0.4 
mP2 or hP2  [100µM] - 0.4 - 0.4 
mP3 or hP3 [100µM] 0.4 - 0.4 - 
mP4 or hP4 [100µM] 0.4 - 0.4 - 
Pfu Polymerase [2.5U/ml] 2 2 2 2 
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PCR – program 1: 
1) Hot start (to uncoil plasmid DNA): 3min, 94°C → hold (then primers and 
polymerase were added) 
2) 10 cycles: 94°C for 30sec, touchdown from 65°C to 55°C for 45 sec, 72°C for 
45sec 
3) 25 cycles: 94°C for 30sec, 55°C for 45sec, 72°C for 45sec (1sec up, per cycle) 
4) 72°C for 10min 
5) Hold: 8°C o/n 
 
The oligonucleotide primers which were used to generate the fragments were 
partially complementary at their 5´ends to the adjacent fragment, which means that 
the produced TREM-2 fragment had a 5´overhang complementary to DAP12 and the 
DAP12 fragment had a 5´overhang complementary to TREM-2 (Fig. 6, Fig.22). 
 
Fig.6: Scheme for the generation of TREM-2 and DAP12 fragments with overlapping regions (Step 1) 
After purification and determination of the concentration the generated fragments 
were fused together in a 2nd PCR step, without adding primers (Fig. 7). 
PCR – mix 2: 
Fragment Mouse TREM-2/DAP12 
chimera 
Human TREM-2/DAP12 
chimera 
mC1 mC2 mC3 mC4 hC1 hC2 hC3 hC4 
H2O [µl] up to 50µl 
10 x Polymerase buffer 5 5 5 5 5 5 5 5 
dNTPs [10µM] 2 1 1 1 1 2 2 1 
Pfu Polymerase [2.5U/ml] 2 1 - 2 1 2 - - 
Klenow Polymerase [5U/ml] - - 1 - - - 2 1 
mDAP12* [pmol] 0.5 0.5 0.2 0.2 - - - - 
hDAP12* [pmol] - - - - 0.5 0.2 0.2 0.2 
mTREM-2* [pmol] 0.5 0.2 0.2 0.2 - - - - 
hTREM-2* [pmol] - - - - 0.5 0.2 0.2 0.2 
 
* fragments generated in step 1 
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PCR – program 2: 
25 cycles: 94°C for 30sec, 48°C for 25min, 72°C for 5min 
 
 
Fig.7: Scheme for fusion of the fragments without primers (Step 2) 
The 50µl PCR-mix from step 2 was then directly used as a template for the 
amplification of the fused construct in step 3.  
PCR – program 3: 
1) 10 cycles: 94°C for 30sec, touchdown from 65°C to 55°C for 45 sec, 72°C for 
45sec 
2) 25 cycles: 94°C for 30sec, 55°C for 45sec, 72°C for 45sec (1sec up per cycle) 
3) 72°C for 10min 
4) Hold: 8°C o/n 
 
In this 3rd PCR only a forward primer for TREM-2 and a reverse primer for DAP12 
were added in equimolar amounts (primers P1, P4), which means that only the fused 
construct can amplify. The Klenow polymerase was not working at all. Positive results 
were obtained with the batches with lower dNTP concentrations and higher template 
amounts. The obtained chimeric fragments were separated on 1.2% agarose gel 
(Fig. 8, Fig. 23) and purified with a DNA purification kit. 
 
 
Fig.8: Scheme for the amplification of the fusion product (Step 3) 
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5.2.2.2. Cloning into pIRES vector 
To clone the chimeric fragments into a pIRES vector, restriction sites for EcoRI and 
XhOI were introduced by PCR (primers: P5, P6), the fragments were separated on a 
1.2% gel and purified with a DNA purification kit. 
 
PCR – program for the introduction of restriction sites for XhOI and EcoRI: 
Fragment 
Mouse TREM-2/DAP12 
chimera 
human TREM-2/DAP12 
chimera 
mC1 mC2 mC3 mC4 hC1 hC2 hC3 hC4 
H2O[µl] 32.2 33.2 37.2 37.7 32.2 33.2 37.2 37.7 
10 x HiFi buffer [µl] 5* 5 5* 5 5* 5 5* 5* 
dNTPs (10µM) [µl] 1 0.5 1 1 1 0.5 1 1 
Hi Fidelity Polymerase (5U/ml) [µl] 1 0.5 1 0.5 1 0.5 1 0.5 
mP5/hP5 [µl] 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 
mP6/hP6 [µl] 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 
Template [µl]** 10 10 5 5 10 10 5 5 
 
* instead of the 10x Hi fidelity buffer, the 10x Pfu buffer was used to try a different Mg2+ concentration 
** purified chimeric fragment from step 3 (cmChimera = 28.2 ng/µl, chChimera = 23.3 ng/µl) 
 
Empty pIRES vector and the fragments were digested with EcoRI and XhOI for 1h at 
37°C in a total volume of 25µl. 
 mouse human pIRES x 2 
H2O [µl] 6.25 6.25 20.45 
10 x buffer H 
[µl] 2.5 2.5 2.5 
XhO1 [µl] 0.25 0.25 0.25 
EcoR1 [µl] 1 1 1 
DNA 15 15 0.8 
 
The vector was treated with alkalic phosphatase (AP) to avoid relegation (pIRES 
restriction mix + 1µl AP + 1µl H2O + 3µl 10x AP buffer for 10min at room 
temperature) and purified by gel separation to remove the AP buffer. Vector and 
inserts were ligated at 15°C over night in a 1/2 and a 1/3 ratio (vector/insert ratio). 
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nginsert (for a 1:1 ratio) = 50 (ngvector) x 0.74 (kbinsert)/ 5.3 (kbvector) 
 mouse human 
 3:1 2:1 3:1 2:1 
H2O [µl] - 1.5 2.8 4.3 
T4 ligase [µl] 3 3 3 3 
10x ligation buffer [µl] 1.5 1.5 1.5 1.5 
Insert [µl] 8 5.8 4.5 3 
pIRES 3.2 3.2 3.2 3.2 
 
Subsequently the constructs were transformed into competent DH5α E.coli cells. 
(protocol for heat shock transformation of E.coli see appendix). 
Transformants were inoculated in 5ml LB media (+ Kanamycin), grown over night at 
37°C and plasmids were isolated by mini prep (Quiagen kit). To test for insertion in 
the right direction a control digest of the plasmids was performed with XhOI and 
BamH1. 
 
5.2.2.3. Site directed mutagenesis 
The TREM-2/DAP12 chimera transmembrane mutant (TM-mutant) was generated by 
exchanging the aspartic acid (D) at position +9 in the transmembrane part of DAP12, 
which has been shown to be required for association with other receptors [107], with 
alanine (A) using the Quickchange site directed mutagenesis kit (Stratagene) 
according to the manufacturer’s instructions. In this reaction 2 primers, which are 
complementary to each other and are carrying the mutation, are used for a PCR 
amplification of the original construct in a vector, using PfuTurbo DNA polymerase. 
The incorporation of the oligonucleotide primers generates a mutated plasmid 
containing staggered nicks. After PCR the mixture is incubated with Dpn I 
endonuclease, which digests the methylated, parental DNA and thereby selects for 
the new, mutation-containing DNA. For the mouse fusion construct the mutagenesis 
worked immediately, a mutagenesis of the human fusion construct failed. 
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5.2.2.4. Gateway cloning 
The Gateway Technology cloning system is based on the bacteriophage λ site-
specific recombination system, which enables the phage to integrate into the E.coli 
chromosome and to switch between the lytic and lysogenic pathway. The 
recombination occurs between specific attachment (att) sites on the interacting DNA 
molecules. Upon integration of the phage, recombination occurs between attB sites 
on the E.coli chromosome and attP sites on the λ chromosome mediated by 
enzymes λ integrase (Int) and the integration host factor (IHF) (BP clonase). This 
reaction is called the BP reaction and is used by the phage for the lysogenic 
pathway. The BP reaction gives rise to attL and attR sites. These sites are required 
for the phage to excise the integrated DNA from the E.coli chromosome and start the 
lytic pathway. This reaction is called the LR reaction and is mediated by Int, IHF and 
the λ-phage encoded enzyme Excisionase (Xis) (LR clonase) (Fig. 9). 
 
 
Fig.9: BP and LR reaction scheme, adapted from the Gateway Technology manual 
 
After adding att sites to the constructs by PCR (primers: P9, P10, P11, see supp. Fig. 
5), the fragments were cloned into a gateway compatible shuttle vector (pDONR201) 
with a BP reaction in order to clone the constructs into Gateway destination vectors 
which contain the TAP-tag (pRVNTAP GS2xT Gw for retroviral transfection of RAW 
cells), or the Strep-HA tag (pTO HA StrepIII GW FRT for the transfection of HEK 
cells), with an LR reaction. 
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BP reaction 
 [µl] 
H2O [µl] up to 10 
pDONR201 [µl] 1 
5x BP clonase reaction buffer [µl] 2 
attB containing construct (40 – 100fmol) 8 
LR reaction 
H2O [µl] up to 10 
Entry vector [µl] 1 
5x LR clonase reaction buffer [µl] 2 
Construct in pDONR201 [µl] 1 
 
 
5.2.3. Production of stable transfected cell lines 
5.2.3.1. Viral transfection on RAW 264.7 cells 
GP-293 HEK cells (packaging cell line, Clontech) were grown to a confluency of 70% 
and transfected with the constructs. 2µg VSV-G (retroviral vector) was mixed with 
300µl serum free DMEM, 8µg of the pRVNTAP GS2xT Gw vector containing the 
construct and. 100µl Polyfect and the, the mixture was incubated for 10min at room 
temperature. Subsequently, 700µl of HEK media was added, the solution mixed and 
carefully dropped on the cells. Media was removed 12h post incubation and 6ml fresh 
HEK media was added and the cells were incubated for another 24h at 37°C. Target 
cells (RAW264.7) were seeded out in a 6 well plate at a density of 5*105/well. 
3 days post transfection, media was exchanged on the target cells (1ml) and they 
were infected with the virus. The supernatant of the HEK cells (containing the virus) 
was taken off (6ml), spun for 5min at 1200rpm and the HEK cells were carefully 
covered with another 5ml of fresh HEK media.  Media was removed from the RAW 
cells and ~5ml of centrifuged, virus containing supernatant was added. 24h post viral 
infection.  
RAW cells were transferred into 10cm dishes (with RdB) and a second viral 
transfection round was carried out on day 4, analogous to the procedure on day 3. 
The HEK cells were discarded and the RAW cells were expanded for FACS sorting. 
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5.2.3.2. Selection for positive RAW 264.7 cells by FACS 
Before cell sorting, the cells were checked for GFP positivity cells by FACS analysis. 
Briefly,  they were plated in a 6 well dish and cultured to   100% confluency, removed 
using RdB, washed twice with 2ml PBS (3% BSA), resuspended in 300µl of PBS (3% 
BSA) and analyzed for GFP positivity using FACS calibur (BD Biosciences). 
Since 3-5% of the cells were shown to be GFP positive, the cells were sent for 
sorting (Peter Prinz, St. Anna Kinderspital, Vienna) and after sorting another FACS 
for GFP positive cells showed around 80-90% GFP positive cells. 
 
5.2.3.3. Transfection of Flp-InTM T-RExTM HEK 293 cells 
The procedure was based on the work of Glatter et al. [108], who described a novel 
integrated method for the study of protein complexes, optimizing systematic affinity 
purification coupled with mass spectrometry based research. Cells were grown to 
confluency in a 15cm plate and split 24h before transfection to 5 x 6-well plates (4ml 
media/well). For transfection, 6µl of Fugene6TM was added to 100µl of serum free 
DMEM (transfection reagent) and the mixture was incubated for 5min at room 
temperature. 200ng of the constructs in the destination vector were mixed with 1µg of 
pOG44, the transfection reagent was added, and the mixture was incubated for 
another 15min at room temperature before drop wise addition to the cells. 
 
5.2.3.4. Selection of Flp-InTM T-RExTM HEK 293 cells 
After 2 days incubation at 37°C, the cells were expanded to 10cm dishes. The next 
day, medium was removed and exchanged with media containing 38µg/ml Blasticidin 
and 260µg/ml Hygromycin to allow for selection. Media was now removed every five 
days to remove dead cells. The surviving cells were again cultured until they reached 
confluency and. detached from the plate and frozen in liquid N2 and stored at -80°C 
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4.2.2.9 Pulldown experiment with Flp-InTM T-RExTM HEK 293 cells 
Cells were expanded to 5x 15cm plates, grown to 70-80% confluency and expression 
induced by addition of 1µg/ml Doxicyclin. 24h post Doxicyclin treatment, each plate 
was washed with 10ml cold PBS (supplemented with 0.1mM MgCl2 and 0.1mM 
CaCl2) and the cells were harvested with PBS containing 1mM EDTA, centrifuged, 
snap frozen in liquid N2 and stored at -80°C. 
The frozen pellet was resuspended in 5ml HNN-lysis buffer (1ml/dish) with Avidin, 
incubated on ice for   10min and spun down (13K, 20min, 4°C). During centrifugation 
Strep Tactin sepharose beads were equilibrated, by loading 400µl slurry on BioRad 
Biospin columns (#732-6008) and washing twice with 1ml HNN-lysis buffer without 
Avidin. 
Before purification an aliquot of the lysate was taken for western blotting. 
For the first purification step the lysate was slowly added to the beads (lysate entered 
the resin by gravity flow). The beads were then washed 3x with HNN-Lysis buffer and 
elution was performed by adding 3x 200µl and 1x 300µl HNN-buffer with 
supplements, containing 2.5mM Biotin. 
For the second purification step, 100µl anti-HA beads (Anti-HA Agarose, Sigma 
A2095) (200µl slurry)/ sample were washed 1x in HNN-Lysis buffer, spun  down for 
1min at 1000rpm and resuspended in HNN-Lysis buffer. The beads were then added 
to the eluate from the first purification and incubated for 1h on a rotating shaker at 
4°C. The suspension was transferred into a new column, the beads were washed 3x 
with 1ml HNN-lysis buffer (with NP40 and inhibitors) and 2x with 1ml HNN buffer 
(without NP40 and inhibitors). Then elution was done by adding 5x 100µl 0.2M 
Formic acid, pH 2.5 and the eluate was neutralized by adding 160µl of 1M NH4CO3 
(pH 8.8). Before the samples were flash frozen in vials for mass spectroscopy, 
another aliquot was taken for western blotting. 
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5.2.4. Stimulations 
All stimulations for western blotting were performed in serum free media. All others 
(ELISA, Confocal microscopy) were carried out in presence of 10% FCS. 
HEK cells were stimulated with heat killed S. pneumoniae. at a concentration of 2*108 
CFU/ml, RAW cells and alveolar macrophages with a concentration of 2*107 CFU/ml. 
LPS from E.coli was used as a control at a concentration of 1µg/ml. 
 
5.2.5. Killing assay 
S. pneumoniae was grown according to supplementary protocol (appendix). Cells 
were plated in a 24 well-dish at a density of 2*105/well in RPMI with 10% FCS (no 
antibiotics), left in the incubator for 3h to adhere, washed 2x with PBS and covered 
with 500µl fresh media. S. pneumoniae was added to the wells (MOI 100) and spun 
on to the cells by centrifugation (2000rpm, 5min, 4°C). Cells were incubated  at 37°C 
for 10min to allow phagocytosis and subsequently all wells were washed five times 
with ice cold PBS to remove extracellular bacteria. Cells from 3 wells were 
immediately lysed after washing in 1ml ddH2O (timepoint 0). The other cells were 
covered with 500µl fresh media and incubated at 37°C.  5, 10, 30 and 60min post 
incubation, another 3 wells were washed three times each with ice cold PBS and 
lysed in 1ml of ddH2O. The lysates were then diluted 1:10 in saline up to a dilution of 
10-3 and 50µl of each dilution was dropped on blood agar plates. CFUs were counted 
on the next day.  
 
5.2.6. Enzyme-linked Immunosorbent Assay (ELISA) 
Retroviral transfected RAW cells were plated in a 96-well dish with a density of 4 * 
105/well and stimulated the next day with heat killed S. pneumoniae (2 * 107 CFU/ml) 
for 6h and 20h. TNFα and IL-6 levels were in the supernatant using ELISA (R&D). 
Samples were diluted in ELISA washing buffer with a ratio of 1:2 for the 6h 
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stimulation and 1:5 or 1:10 for the 22h stimulation. Fluorescence activated cell sorting 
(FACS)  
2 x 105 cells per sample in 100µl of FACS buffer (PBS containing 3% BSA) was 
incubated for 20 min in the dark with either   anti TREM-2 antibody (1:50 or 1:10 
dilution) or isotype control antibody (1:50 dilution). Subsequently, cells were washed 
with 1ml FACS-buffer centrifuged (1250rpm, 5 min), supernatant removed and 
TREM-2 surface expression measured by FACS analysis. 
 
5.2.7. Confocal microscopy 
Cells were plated at a density of 1-3 x 105/well in 8-well chamberslides (Lab-Tek 
Chamberslide system) and incubated over night at 37°C. All incubation steps were 
performed at room temperature except the incubation with the primary anti-TREM-2 
antibody, which was carried out at 4°C  
Cells were washed twice with 200µl PBS and fixed by covering them with a solution 
of 3.7%PFA for 10min. Subsequently, PFA was removed by washing twice with PBS 
and cells were blocked using 1%BSA in PBS for 0.5h.  
For the TREM-2 staining the cells were blocked with PBS with 10% serum (mouse 
and rabbit were tried) and 1% BSA for 0.5h. For the TREM-2 staining, cells were after 
blocking incubated over night with anti TREM-2 antibody diluted 1:50 in PBS for the 
surface staining and in PBS with 0.1% Triton-X for the intracellular staining over night 
at 4°C. After three times washing with PBS, cells were incubated with the secondary 
FITC labeled antibody diluted 1:400 in PBS for the surface staining and in PBS with 
0.1% Triton-X for intracellular staining for 30min.From this time on, the cells were 
protected from light. After the staining the cells were again washed three times with 
PBS. For the actin staining, Alexa Fluor-conjugated phalloidin was diluted from the 
stock (6.6µM) 1:600 in PBS with 1% BSA and added on the cells (after blocking and 
washing) and incubated in the dark for 20-30min, followed by two washing steps with 
PBS. Visualization of the nucleus was achieved by covering the cells with a DAPI 
solution in PBS (1µg/ml) and incubated for 10min in the dark. 
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For the phagocytosis experiment, cells were stimulated before fixation with FITC-
labeled heat killed S. pneumoniae with an MOI of 100 for 1h, together with 
Lysotracker (60nM), which marks lysosomes because of their low pH. After 
stimulation cells were fixed and the nucleus stained with DAPI as described above. 
After the last washing step, the cover of the chamber slide was removed and shortly 
air dried. Cells were covered with a coverslide (24 x 50mm, VWR) using mounting 
media (Fluoprep). Slides were visualized via confocal microscopy (Zeiss LSM 510). 
 
5.2.8. Preparation of cell extracts 
All extracts which were prepared without denaturing conditions were made on ice, 
freshly prepared buffers and tubes were pre-chilled.  
 Macrophages were washed with PBS, covered with WCE buffer and left on ice for a 
couple of minutes, scratched off from the well and transferred into eppendorf tubes. 
HEK cells which were easy to detach were directly transferred in eppendorf tubes 
and covered with WCE lysis buffer. The amount of lysis-buffer was dependent on the 
amount of cells (5x105 – 5x106), ranging from 75µl to 200µl.  Cells were passed 
through a 25G needle ten times, left on ice for 30min, spun at 14000rpm,  4°C,  
10min  and   supernatant was  transferred into a fresh pre-chilled eppendorf tube, 
frozen in liquid N2 and stored at -80°C. The protein concentration was measured by 
Bradford. 
Because of the huge amount of cells which are required for whole cell extracts, cells 
were also lysed directly in hot (95°C) SDS-sample buffer, if the samples were used 
for western blotting. The disadvantage of this method is, that it is not possible to 
determine the protein concentration, so it is necessary to precisely plate equal 
amounts of cells and use equal amounts of lysis-buffer. 
 
 
 
Riem Gawish Diplomathesis 2009/2010 
54 
 
5.2.9. SDS-Page 
Samples which were directly lysed in SDS-sample buffer were boiled for 5min at 
95°C and directly used, without determining the protein concentration. 25µg of 
protein were loaded from samples which have been lysed in WCE lysis buffer. The 
samples were 1:1 diluted with 2x SDS-sample buffer and boiled for 5min at 95°C 
prior to gel loading. Samples were loaded to a 10% or 12% SDS-page  gel and 
electrophoresis was performed for 1h at 120V (Biorad MiniProtean electrophoresis 
System). 
 
5.2.10. Western blot analysis 
1x semi-dry blotting buffer was prepared by dilution of the 10 x stock 1 in 10, with 
ddH2O and adding 20% Methanol (Sigma; M1770). Proteins were blotted onto a 
PVDF membrane (Biorad, Immun-blot PVDF membrane, 0.45µM poresize) using 
semi-dry transfer for 1h at 10-12V (Biorad Transblot SD semidry transfer 
cell).Membranes were blocked with either PBS containing either 5% BSA or 5% milk 
powder for 1h at room temperature. If milk was used for blocking, the membranes 
were washed twice with PBST (0.1% Tween20) before incubation with the primary 
antibody.  
The primary antibodies were used in a dilution of 1:1000 in PBST with 2% BSA and 
incubated over night on a shaker at 4°C. If the signal was very weak the membrane 
was incubated with the primary antibody on the next day for another 1-2h at room 
temperature. Subsequently, membranes were washed three times 15min with PBST 
and incubated with secondary, fluorescently labeled antibody in PBST with 2% BSA  
at a concentration of 1:20000 (Rockland) or 1:15000 (Licor). The  membrane was  
washed three times for 15min with PBST, to reduce the background in the last 
washing step 0,01% SDS was added to the washing buffer. Detection was performed 
using Licor Odyssey infrared imaging System. . 
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6. Results 
6.1. TREM-2 and phagocytosis 
6.1.1. Enhanced phagocytosis by TREM-2 -/- AMs 
As mentioned before, TREM-2 deficient AM have been shown to exert an increased 
phagocytic activity in a FACS based phagocytosis assay (Fig. 10), when stimulated 
with FITC-labeled S. pneumoniae or E.coli (O. Sharif, unpublished data).  
 
Fig.10: FACS based phagocytosis assay after stimulation of WT and TREM-2-/- AMs with FITC-
labeled S. pneumoniae (O. Sharif unpublished data) 
Since this result was very surprising and is in conflict with previous publications, 
which identified TREM-2 as a phagocytic receptor [95], the idea was to verify this 
result using another method. Therefore, confocal microscopy on AMs from WT and 
TREM2-/- mice incubated with FITC labeled bacteria was conducted. 
Fig.11 and 12 shows WT (left) and TREM-2-/- (right) AMs with ingested FITC-labeled 
S. pneumoniae. (green). Nuclei are visualized in blue, in red lysosomes are seen, 
stained with Lysotracker. Depending on the intensity of the Lysotracker staining the 
color of the bacteria ranges from yellow to green. 
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Fig.11: Confocal microscope picture of WT and TREM-2-/- AMs with ingested FITC-labeled bacteria 
Cells positive negative total % positive 
WT AMs 
54 26 80 67,50 
11 12 23 47,83 
60 74 134 44,78 
48 58 106 45,28 
TREM-2-/- AMs 
57 20 77 74,03 
53 29 82 64,63 
56 15 71 78,87 
37 14 51 72,55 
 
 
Fig.12: Calculation of the percentage of cells which were phagocytosing bacteria 
Four squares were counted and the percentage of positive cells was calculated (Fig. 
12). The amount of ingested bacteria was not considered. Every cell containing any 
bacteria was counted as positive. From this result the conclusion was that TREM-2 
deficient AMs indeed phagocytose more S. pneumoniae compared to wildtype cells. 
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6.1.2. Elevated PI3 Kinase activity in TREM-2 -/- AMs 
After verifying that TREM-2 deficient AMs have a higher phagocytic activity, when 
challenged with S. pneumoniae, the question evolved which mechanism was 
responsible for this increased uptake. PI3-Kinase has been shown to be involved in 
the regulation of cytoskeletal reorganization during phagocytosis [57]. AKT is an 
important target of PI3-Kinase. When stimulated with S. pneumoniae, TREM-2-/- 
AMs show higher levels of phosphorylated AKT (Thr308) (Fig. 13), whereas levels of 
the phosphorylated PI3-Kinase antagonizing phosphatase PTEN (Ser380) did not 
differ between genotypes (Fig. 14), indicating equal activity of PTEN.  
 
 
 
 
 
 
Fig.13: Elevated levels of AKT phosphorylation in TREM-2-/- AMs 
 
 
 
 
Fig.14: Equal phosphorylation levels of PTEN in WT and TREM-2-/- AMs 
 
A FACS based phagocytosis assay showed that treatment of the cells with the PI3-
kinase inhibitor wortmannin equalizes the phagocytosis of WT and TREM-2-/- AMs 
(unpublished data, O. Sharif), suggesting that enhanced PI3-kinase in TREM-2 
deficient cells might be responsible for the enhanced phagocytic activity.  
WT AMs 
WT AMs TREM-2-/- AMs 
TREM-2-/- AMs 
60 60 LPS LPS 30 30 15 15 0 0 
41 kDa β-Actin 
54 kDa phospho PTEN 
41 kDa β-Actin 
60 kDa phospho AKT 
0 0 15 15 30 30 60 60 
[min] stimulated with S. pneumoniae 
[min] stimulated with S. pneumoniae 
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Surprisingly also the levels of phosphorylated glycogen synthase kinase-3β (GSK-3β) 
remained unaffected (Fig. 15), which is an important substrate of activated AKT. AKT 
phosphorylates and thereby inactivates GSK-3β. It has been published that active 
GSK-3β is important in the regulation of TLR-mediated cytokine production [109]. 
 
 
 
 
Fig.15: Equal phosphorylation levels of GSK-3β in WT and TREM-2-/- AMs 
 
6.1.3. More ERK-phosphorylation in TREM-2 -/- AMs 
It has been shown that there is enhanced phosphorylation of the MAP kinase ERK in 
DAP12 deficient bone marrow derived macrophages [110]. Therefore, it is likely that 
TREM-2 deficiency may impact this MAP-kinase. Indeed, upon stimulation with S. 
pneumoniae, TREM-2-/- AMs show higher levels of ERK1/2 phosphorylation 
compared to WT AMs (Fig. 16). 
 
 
 
 
Fig.16: Elevated levels of ERK1/2 phosphorylation in TREM-2-/- AMs 
 
0 15 30 30 15 60 60 0 [min] stimulated with S. pneumoniae 
WT AMs TREM-2-/- AMs 
42kDa 
44kDa 
41 kDa β-Actin 
ERK1/2 
WT AMs TREM-2-/- AMs LPS control 
0 0 30 30 30 30 60 60 
41 kDa β-Actin 
46 kDa phospho GSK-3β 
[min] stimulated with S. pneumoniae 
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Although, there was not enough protein loaded for the unstimulated WT sample, this 
result was observed in another independent experiment, but the differences between 
WT and TREM-2-/- AMs was smaller (data not shown). Nonetheless, in both 
experiments highest levels of phospho-ERK were seen after 30min stimulation and 
then decreased again (Fig 16). 
Phosphorylation of the MAP-kinase p38 seemed to be unaffected at least at 15 min 
(Fig. 17), which is a phenotype similar to DAP12-/- BMDMs stimulated with LPS 
[110]. It is difficult to conclude something from the 60 min time point due to 
insufficient protein amounts in the TREM2-/- 60 min sample.  
 
 
 
 
Fig.17: Equal activation of p38 in WT and TREM-2-/- AMs 
 
 
 
 
 
 
 
 
 
 
WT AMs TREM-2-/- AMs 
0 15 60 60 15 0 
LPS control 
30 
 
30 
 
41 kDa β-Actin 
38 kDa phospho p38 
[min] stimulated with S. pneumoniae 
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6.1.4. Analysis of the actin cytoskeleton by confocal microscopy 
Since it has been published that TREM-2 deficiency leads to aberrant organization of 
the actin cytoskeleton in DCs and in osteoclasts [82, 99], filamentous actin (F-actin) 
of WT and TREM-2-/-  AMs was  stained with Alexa Fluor-coupled phalloidin and 
visualized by confocal microscopy to determine  whether TREM2  deficiency has a 
similar effect in alveolar macrophages (Fig. 18).  
 
 
Fig.18: Staining of F-actin with Alexa Fluor-conjugated phalloidin of WT AMs (left) and TREM-2-/- AMs 
(right) 
Both cell types, WT and TREM-2-/- AMs, have a round shape and show no visible 
differences in the amount of protrusions or cell size (~ 10µm). Furthermore, the 
distribution of F-actin seems so be the same, but interestingly the signal intensity of 
TREM-2 deficient AMs was lower. This result was obtained in two independent 
experiments, when WT and TREM-2-/- cells were visualized with the same settings. 
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6.1.5. TREM-2 has no effects on the killing properties of AM 
Since TREM-2-/- AMs  show enhanced phagocytosis, the question was if these cells 
also show differences in their ability to kill ingested bacteria. To answer this question 
a killing assay was performed to compare the killing properties of WT and TREM-2-/- 
AM and showed that TREM-2 deficiency does not affect the killing of ingested S. 
pneumoniae (Fig. 19). 
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Fig.19: Killing curve of S. pneumoniae. of WT vs. TREM-2-/- AMs 
 
6.2. TREM-2 staining 
It has been previously observed that TREM-2 is located intracellular in the Golgi 
apparatus of microglia [86]. Therefore, we wanted to determine whether it was 
intracellularly located in AMs, but it turned out to be difficult because of the lack of 
good antibodies. The secondary antibody caused a very strong unspecific signal on 
cells which were not pretreated with the primary anti TREM-2 antibody. Blocking with 
1% BSA and 10% mouse serum finally worked, but still needs to be optimized. 
Intracellular staining for TREM-2 showed TREM-2 to be localized in small 
aggregates, distributed within the whole cell (Fig. 20), similar to the “puncta” which 
were observed by Prada et al. in microglia N9 cells. These puncta were also 
observed extracellular in cells which were stained with and without triton-X. The 
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surface staining looked different and showed a more homogenous distribution of 
TREM-2 than in the cells which were treated with detergent (Fig. 20), indicating that 
TREM-2 is homogenously expressed on the cell surface. The intracellular staining 
might give evidence for the intracellular localization of TREM-2, but needs to be 
repeated with another detergent.  
 
  
 
 
 
 
 
 
Fig.20: Staining of TREM-2 in WT AMs: intracellular (left) and surface (right) 
Controls with the secondary antibody without pre-treating the cells with the primary 
antibody still gave a weak signal (Fig. 21), even after blocking with serum, but luckily 
there was a significant difference in the intensity between the TREM-2 stained cells 
and the unspecific signal from the secondary antibody. 
 
Fig.21: Staining of WT AMs stained only with the secondary antibody in a dilution of 1:400 
Riem Gawish Diplomathesis 2009/2010 
63 
 
6.3. Generation of a TREM-2/DAP12 chimeric construct 
The production of TREM-2/DAP12 chimeric constructs for transfection into RAW cells 
(mouse) and for transfection into HEK cells (human) was successful after couple of 
trials. The production of overlapping fragments or TREM-2 and DAP12 (mouse and 
human) is seen in Fig. 22 and worked well.  
 
 
Fig. 22: Gel electrophoresis of the fragments generated in Step 1 (2% agarose gel) for purification of 
TREM-2 and DAP12 fragments generated in Step 1 (mTREM2 519bp, mDAP12 276bp, hTREM2 
528bp, hDAP12 273bp 
 
Especially the second PCR step, when the fusion of the TREM-2 and DAP12 should 
take place turned out to be a highly sensitive process, which doesn´t work anymore 
when the dNTP concentration is too high or the template concentration too low. After 
the third PCR step DNA fragments with the expected size of the chimeric molecule 
(hChimera 777bp, mChimera 771 bp) were obtained (Fig. 23) 
 
 
 
  
Fig. 23: Gel electrophoresis of the amplified fusion products generated in Step 2 and 3 
 
By PCR the fusion constructs were amplified and restriction sites for cloning into 
pIRES were introduced (Fig. 24). 
hC1      hC2       hC3    hC4             mC1     mC2      mC3    mC4             bp 
700 
500 
700 
mTREM-2 mDAP
 
hTREM-2 hDAP12 bp 
500 
250 
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Fig. 24: Gel electrophoresis (1.2% agarose) of the TREM-2/DAP12 chimera with restriction sites for 
EcoRI and XhOI 
 
After cloning into the pIRES vector, a control digest with BamHI showed all clones to 
have the fragment inserted in the right direction. The fragment in pIRES was used for 
the production of a TM-mutant chimera by site directed mutagenesis, which was 
successful.  
All constructs were cloned into the gateway donor vector pDONR201 and a control 
digest with Pst1 was performed (Fig. 25). Subsequently the constructs were cloned 
into the corresponding destination vectors, hTREM-1 and hTREM-2 into pTO HA 
StrepIII GW FRT, mTREM-2, mTREM-1, mTREM-2/DAP12 chimera and the TM-
mutant chimera into pRVNTAP GS2xT Gw. mTREM-1 was ordered in a gateway 
compatible donor vector and a PstI control digest was performed after the LR 
reaction (Fig.25). 
 
 
Fig. 25: Gel electrophoresis (1.2% agarose) of the mouse construct in pRVNTAP GS2xT Gw and the 
other constructs in  pDONR201 after digest with Pst1.  
  1       2       3      4        1      2       3       4                  bp 
    mChimera          hChimera 
mTREM-2 mChimera mTM-mutant mTREM-1 hTREM-1 hChimera hTREM-2 
700 
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All constructs showed to be positive and were sent for sequencing. Unfortunately the 
human TREM-2/DAP12 chimera showed to have a point mutation in the TREM-
2/DAP12 overlapping region (sequencing results not shown) and was therefore not 
used for the production of stable transfected HEK cells. 
 
6.4. Stable transfected cell lines 
RAW 264.7 cells transfected with GFP, TREM-1, TREM-2, TREM-2/DAP12 chimera 
or the TM-mutant chimera were generated, as well as Flp-InTM T-RExTM HEK 293 
cells carrying TREM-2 and TREM-1 with a Doxycyclin inducible promoter. In both 
cases the transfection was successful, but the constructs failed to be expressed by 
the cells on protein level. 
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6.4.1.  FACS of transfected RAW 264.7 cell-lines 
A selection for transfected RAW cells was done by sorting the cells for GFP positive 
cells. Before cell sorting, ~5% of transfected RAW cells showed expression of GFP, 
indicating that they were successfully transfected with the construct. After sorting 80-
90% of the cells expressed GFP (Fig. 26) 
 
 
Fig.26: GFP expression of sorted, retrovirally transfected RAW cell lines, (A) untransfected control 
RAW cells, (B) GFP transfected control RAW cells, (C) TREM-1 transfected RAW cells, (D) TREM-2 
transfected RAW cells, (E) TREM-2/DAP12 chimera transfected RAW cells, (F) TM-mutant chimera 
transfected RAW cells 
 
Although the cells showed GFP positivity indicating successful transfection, neither 
the TREM-2 transfected cell line nor the cell lines transfected with the fusion 
constructs showed overexpression of TREM-2, when the cells were stained with a 
(A) (B) (C) 
(D) (E) (F) 
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TREM-2 antibody. Low levels of endogenous TREM-2 surface expression were 
detectable (Fig. 27, A-D), although the antibody should be used in a higher 
concentration. Importantly, TREM-2 expression was not elevated in the TREM-2 
transfected RAW cells compared to the GFP-transfected control RAW cells (Fig. 27, 
E). The conclusion was that the constructs were most likely not expressed well or 
might get dislocalized and degraded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.27: TREM-2 FACS of stable transfected RAW cells, 
TREM-2 APC measured in FL4-H (A) GFP transfected RAW 
cells (green) blotted against the Isotype control (pink), (B) 
TREM-2 transfected RAW cells (dark-blue) blotted against 
the Isotype, (C) TREM-2/DAP12 chimera transfected RAW 
cells (blue) blotted against the Isotype, (D) TM-mutant 
chimera transfected RAW cells (turquoise) blotted against the 
Isotype, (E) TREM-2 expression of GFP transfected RAW 
cells versus TREM-2 transfected RAW cells 
(D) 
(A) (B) 
(C) 
(E) 
(C) 
(E) 
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An intracellular FACS for TREM-2 was performed but failed to detect any TREM-2 
neither intracellular nor on the surface, indicating that the staining was not working 
well. The experiment was not repeated due to the result shown on Fig. 29. 
 
6.4.2. Enhanced levels of IL-6 in transfected RAW cells 
To check functional effects of overexpression of all the constructs, cytokine 
production was measured after stimulating the cells with S. pneumoniae. 
IL-6 production of RAW cells upon stimulation
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Fig.28: IL-6 production of stable transfected RAW cells in response to S. pneumoniae after 6h and 
22h stimulation (Statistic analysis with Graphpad Prism: One way annova, Tukey-test) 
The RAW cell lines, stable transfected with TREM-1, TREM-2 or the chimeric 
constructs, produce significantly more IL-6 (Fig. 28) This is surprising,  since TREM-2 
has been shown to be a negative regulator [80] of the inflammatory response. 
Nonetheless, these cells exhibit higher levels of proteasome activity (Fig 29) 
indicating cellular stress which could have an impact on pro-inflammatory cytokine 
production. 
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6.4.3. Solubility of the constructs expressed by RAW cells 
Since TREM-2 has a singlepass transmembrane domain, which could result in   
unsolubility of the protein, three buffers with different stringency were used to lyse the 
cells and the TAP tag was detected by western blotting with an anti-Myc antibody. To 
check for proteasomal degradation all experiments were carried out with and without 
adding the proteasome inhibitor MG132 (Fig. 29). 
 
 
 
Fig.29: Lysates of untransfected (control) and stable transfected RAW cells in WCE buffer with 1% 
NP40, blotted for the Tag 
 
The same experiment was carried out with two more stringent buffers, one which 
contained 1% Chaps and a RIPA buffer. Since the result was exactly the same as 
with the NP40 buffer, the conclusion was that the NP40 buffer is sufficient to extract 
TREM-2 and the generated constructs. 
Significantly, the TREM-2 constructs are obviously being degraded by the 
proteasome, since they are only detectable after addition of MG132. In case of the 
TREM-1 construct, the band which is visible at ~25kDa is most likely the Tag, which 
was cleaved off from the protein. 
 
 
 
+/- MG132 - - - - - - + + + + + + 
untransf. GFP. TREM-1 TREM-2 Chimera TM-Mutant 
~ 50kDa 
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6.4.4. Pulldown experiment with Flp-InTM T-RExTM HEK 293 cells 
One pulldown experiment was performed with the transfected HEK cells after 
induction of TREM-1 and TREM-2 expression with Doxicyclin, showing the same 
result which was already obtained from the experiments with RAW cells. There was 
only weak expression of the constructs, hardly detectable in the lysate and not 
enough for purification (Fig. 30). 
 
 
 
Fig.30: Lysate and purified eluate of stable transfected HEK cells after induction of N-terminal tagged 
TREM-1 and TREM-2 
 
GFP. TREM-1 TREM-2 TREM-2 TREM-1 GFP. 
Lysate Eluate after purification 
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7. Discussion 
The surface receptor TREM-2 has been shown to be important for bone formation 
[98, 100] and brain homeostasis [89], as well as the regulation of immune responses 
[64]. Since downstream signaling of TREM-2 is still largely unknown, one important 
part of this work was the production of a TREM-2/DAP12 chimeric protein, consisting 
of the extracellular domain of TREM-2 fused to the intracellular domain of DAP12. 
Together with another TREM-2/DAP12 chimera carrying a mutation in the 
transmembrane domain, these constructs should be used as important controls in a 
TREM-2 pulldown in Flp-InTM T-RExTM HEK 293 cells and in RAW 264.7 cells. 
The production of the fusion construct worked well in case of the mouse construct, 
and after several trials also for the human construct (Fig. 13). The introduction of a 
mutation in the transmembrane domain of DAP12 by site directed mutagenesis also 
worked immediately in case of the mouse chimera, but never for the human chimera. 
A sequence analysis of the constructs in gateway destination vectors, verified the 
fidelity of all constructs, except for the human fusion construct, which carried a point 
mutation in the TREM-2/DAP12 overlapping region. This point mutation was most 
likely introduced during the initial PCR steps and might be the reason why the site 
directed mutagenesis never worked. 
Successfully transfected RAW 264.7 cells were selected by sorting them according to 
GFP expression (Fig. 26), HEK cells were selected for antibiotic resistance and 
survival. Unfortunately although the RAW cells expressed GFP, indicating that they 
were successfully transfected, they did not show any over-expression of TREM-2 in a 
FACS analysis (Fig. 27). A pulldown experiment with the HEK cells also showed only 
weak expression of TREM-2 and TREM-1 (Fig. 30). Since solubility turned out not to 
be the problem, we hypothesized that the constructs might get degraded. Indeed, 
cells pretreated with the proteasome inhibitor MG132 before lysis, expressed the 
TREM-2 constructs, as detected by western blotting with an antibody against the tag 
(Fig. 29). In case of TREM-1, MG132 did not change anything and it looks like the 
whole tag was simply cut off (Band at ~25kDa, Fig. 29).  
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Most membrane proteins are targeted to the membrane via an N-terminal localization 
signal, which is recognized by the signal recognition particle (SRP) immediately after 
synthesis, when the polypeptide is accessible [111]. Signal recognition by SRP is 
crucial for the targeting of signal-peptide bearing proteins to the endoplasmatic 
reticulum and for appropriate insertion, by GTP dependent interaction of the 
ribosome nascent chain-SRP complex with the SRP receptor and subsequent 
translocation through a channel called the translocon. The signal peptide is usually 
cleaved off after insertion [111, 112].  
The decision to tag the pulldown constructs on the N-terminus was based on the fact 
that the intracellular domain of TREM-2 is tiny (~30 amino acids) and that the tag, 
especially the bigger TAP-tag, might interfere with possible interactions. Unluckily the 
tag most likely masked the localization signal in case of the TREM-2 constructs, 
leading to dislocation, and maybe accumulation in the cytoplasm, followed by 
proteasomal degradation. Since I will continue working on TREM-2 during my PhD, a 
C-terminal tagging of TREM-2 might help to overcome the problem of proteasomal 
degradation and will hopefully lead to success.  
Another important part of this work was the characterization of TREM-2 deficient 
alveolar macrophages and their responses upon stimulation with S. pneumoniae. 
In May 2010 Peng et al. showed that the phosphatase SHIP1 negatively regulates 
TREM-2 signaling [113]. TREM-2 ligation induces the recruitment of an activation 
complex including DAP12, DAP10, p85, Syk, and Grb, leading to activation of 
ERK1/2, Vav and AKT. Confocal analysis showed TREM-2 ligation to trigger the 
intracellular co-localization of SHIP1, F-actin, DAP10 and DAP12 in osteoclasts 
[113]. P85 is a regulatory subunit of class IA PI3-kinases, containing an SH2 domain 
which binds to phosphorylated tyrosines [114]. Engagement of P85 domains releases 
PI3-kinases from inhibition and triggers the contact with their lipid substrates in the 
membrane [114]. Upon membrane remodeling SHIP1 gets phosphorylated and  
recruited via its SH2 domain to the phosphorylated Tyr65 of DAP12 in the activation 
complex and converts it into an inhibitory one [113], by preventing additional 
recruitment of p85 or Syk to the complex, and  thereby inhibits activating downstream 
signaling [113]. 
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TREM-2 plays an important role in the pathogenesis of bacterial pneumonia. TREM-2 
deficient mice show a significantly better survival in a survival study of streptococcal 
pneumonia (unpublished data, O. Sharif). Although TREM-2 has been published to 
be a phagocytic receptor for bacteria [95] and to be involved in phagocytosis of 
apoptotic neurons [96], a FACS based phagocytosis assay showed TREM-2 deficient 
AMs to have a higher phagocytic activity when challenged with S. pneumoniae 
(unpublished data, O. Sharif). Because this result was surprising it was verified in this 
work by using confocal microscopy (Fig. 11). The uptake of bacteria was perfectly 
visible and a staining of lysosomes showed partial co-localization of lysosomes and 
bacteria (data not shown). 
Since the PI3- kinase/AKT pathway has been shown to be crucial for lipid remodeling 
[114] and therefore important for phagocytosis [57], we tested whether TREM-2-/- 
AMs show differences in the activation of this pathway. Indeed, western blot analysis 
of WT and TREM-2 deficient AMs showed higher levels of AKT phosphorylation in 
the knockout cells, when challenged with S. pneumoniae (Fig. 13). When  PI3-kinase 
gets activated, it phosphorylates phosphatidylinositol-4,5-bisphosphat (PIP2) 
generating phosphatidylinositol-3,4,5-trisphosphat (PIP3), a process which is 
antagonized by the PIP3 phosphatase PTEN [115]. AKT and PDK1 are recruited to 
the membrane and bind to PIP3 via their plextrin homology (PH) domain. AKT gets 
phosphorylated and activated by PDK1 [116] and mediates a variety of downstream 
signaling processes, inducing cell survival, growth, proliferation and angiogenesis 
[116]. PTEN is equally activated in TREM-2 deficient cells compared to WT (Fig. 14).  
One important downstream target of pAKT is GSK-3β which gets inactivated by 
phosphorylation of the N-terminal Ser9 [115]. GSK-3β is a multifaceted kinase, 
mediating various processes including the regulation of TLR-mediated cytokine 
production [109]. LPS has been shown to activate AKT and inactivate GSK-3β in 
human AMs, leading to nuclear accumulation and increased transcriptional activity of 
β-Catenin [117]. Higher levels of GSK-3β phosphorylation could not be shown in this 
work (Fig. 15). This could be due to  the different qualities of cell extracts, or the fact 
that GSK-3β is regulated via kinases other than AKT, including protein kinase A  
(PKA) [118]. Together with a phagocytosis assay, showing that wortmannin, a PI3-
kinase inhibitor, equalizes the phagocytic activity of WT and TREM-2-/- AMs 
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(unpublished data, O. Sharif), and data from TREM-2 overexpressing HEK 293 cells 
showing lower levels of AKT phosphorylation, compared to normal HEK 293 cells 
when stimulated with S. pneumoniae, these data suggest that TREM-2 negatively 
regulates PI3-kinase activity. This result fits with the observation that the TREM-
2/DAP12 complex recruits p85 in a SHIP1 dependent manner [113] and might also 
serve as an explanation for the increased cytokine responses of TREM-2 deficient 
macrophages in response to TLR stimuli [71]. 
Higher levels of phosphorylated ERK1/2 were also observed in TREM-2 deficient 
cells (Fig. 16), while p38 remained unaffected (Fig. 17). The same pattern has been 
shown for DAP12-/- deficient macrophages, possibly suggesting that TREM-2 is the 
receptor responsible for this effect [110]. 
A killing assay performed with WT and TREM-2-/- AMs showed no differences in the 
killing ability (Fig. 19), but taking into account that both cell types have the same time 
for the uptake of bacteria in this experiment and that TREM-2 deficient cells 
phagocytose more bacteria, this test might not be optimal to compare the killing 
ability of two cell types which differ in their phagocytic activity. 
Since it has been published that TREM-2 is not only expressed on the cell surface, 
but shuttles between the trans-golgi network (TGN) and the cytoplasmic membrane 
in microglia [86], a staining of TREM-2 on AMs followed by confocal analysis was 
performed. Intracellular staining was performed by using Triton-X and TREM-2 was 
visible as accumultated dots (Fig. 20, left), similar to the puncta, which were seen by 
Prada et al. in microglia [86]. In their experiments 0.4% saponin was used, because 
they observed release of TREM-2 from the surface, when cells were treated with 
triton-X. This observation was not reproducible in this study . A surface staining 
showed TREM-2 to be homogenously distributed on the cell surface (Fig. 20, right). 
Despite blocking with 10% serum the secondary antibody alone produced a quite 
strong unspecific signal (Fig. 21), but there was a clear difference  visible between 
the control and cells which were treated with the anti-TREM-2 antibody (Fig. 20 and 
21). 
TREM-2-/- osteoclasts [99] and DCs [82] show aberrant cell morphology, therefore 
the question was if TREM-2 deficiency would also affect the actin cytoskeleton of 
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AMs. No differences could be observed in cell size, shape or the distribution of F-
actin between WT and TREM-2-/- AMs, except for a generally lower F-actin signal in 
TREM-2-/- cells, observed in two independent experiments. The confocal analysis 
performed in this work alone does not support the conclusion that there are lower F-
actin levels in TREM-2-/- AMs, but this could be tested for by FACS analysis in the 
future. Considering that SHIP1 negatively regulates TREM-2 signaling, that TREM-2 
ligation leads to F-actin accumulation and that SHIP1-/- BMDMs contain more F-
actin, it would be worthy to follow up on this observation. . 
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8. Abbreviations 
AEC Alveolar epithelial cell 
AM(s) Alveolar macrophage(s) 
att site attachment site 
BAL(F) Broncho alveolar lavage (fluid) 
BMDM Bone marrow derived macrophage 
CR Complement receptor 
CRP C-reactive protein 
DAG Diacylglycerol 
DAP10 DNAX activating protein of molecular mass 10 kDA 
DAP12 
DNAX activating protein of molecular 
mass 12 kDA, also called KARAP (killer 
cell activating receptor associated 
protein) or TYROBP (tyrosine kinase-
binding protein) 
DC Dendritic cell 
EAE Experimental autoimmune encephalomyelitis 
ER Endoplasmatic reticulum 
ERK1/2 
Extracellular signal regulated kinase1/2 
or mitogen associated protein kinase 
(MAPK)  p42/44 
GFP Green fluorescent protein 
IFNγ Interferon-γ 
IgSF domain Immunoglobuline superfamily-like domain 
IHF Integration host factor 
Iκb Inhibitors of NFκb 
IL-1 Interleukin-1 
Int λ Integrase 
ITAM Immunoreceptor tyrosine-based activating motif 
ITIM Immunoreceptor tyrosine-based inhibitory motif 
LPS Lipopolysaccharide 
LTA Lipoteichoicacid 
MBL Mannose binding lectin 
MOI Multiplicity of infection 
NFκb Nuclear factor-κb, Rel proteins  
NLR NOD-like receptor 
PAMP Pathogen associated molecular pattern 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
Riem Gawish Diplomathesis 2009/2010 
77 
 
PH domain Plextrin homology domain 
PI3-Kinase Phosphatidylinositol 3 Kinase 
PIP2 Phosphatidylinositol-4,5-bisphosphat 
PIP3 Phosphatidylinositol-3,4,5-trisphosphat 
PKA Protein kinase A 
PKC Protein kinase C 
PLOSL 
Polycystic lipomembranous 
osteodysplasia with sklerosing 
leukoencephalopathy or Nasu Hakola 
disease 
Ply Pneumolysin 
PRR Pattern recognition receptor 
PTP Phospho tyrosine phosphatase 
SHIP 
SH2-domain containing 
phosphatidylinositol 3,4,5-trisphosphate 
5-phosphatase 
SH-tag Streptavidin hemaglutinin-tag 
SH2-domain Src homology domain 2 
S.pneu. Streptococcus pneumoniae 
Src Src-kinase 
TAP-tag Tandem affinity purification-tag 
TGN Trans-golgi network 
TIR-domain Toll/Interleukin-1 receptor domain 
TLR Toll-like receptor 
TLT TREM-like transkript 
TM-domain Transmembrane domain 
TM-mutant chimera 
TREM-2/DAP12 chimera carrying a 
mutation in the TM-domain and therefore 
cannot associate anymore with receptors 
TNF-α Tumor necrosis factor-α 
TREM-2 Triggering receptor expressed on myeloid cells-2 
TREM-2-/- TREM-2 knockout 
TREM-1 Triggering receptor expressed on myeloid cells-2 
WT Wildtype 
Xis Excisionase 
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Appendix 
Supplementary protocols 
SOP: Inoculum S. pneumonia 
S. Knapp, 14.02. 2007, Version01 
 
A Start: Strept pneumoniae ATCC 6303 
1 Media TH (Todd Hewitt) 50 ml and 100 ml (Waltraud Schmid, order one week in advance) 
 label: name, species of bacteria, date. 
2 Bacteria (-70°C 3P: Refco Freezer, workspace on the right hand side, second shelf from the 
bottom): S.pneu ATCC 6303, spleen stock 
 In ML-II room (3P): 
3 clean the bench: first with water, and then with 70 % alcohol. Let alcohol dry. 
 Clean Eye gloom in flame, let cool down. Open the flask with TH-media lightly (don`t remove 
the lid) 
4 Make sure that the bacteria are slightly thawed (shake it carefully). Open the tube with the 
bacteria, and load a “glassball” on the Eye. Remove the lid of the TH-media (50 ml tube). Put 
the “glassball” into the media without touching the border of the tube. Close the lid. Close the 
TH-Media. 
5 Take the TH-media with the glassball in the 37 °C room. Then open the lid slightly. Incubate 
for 16 hours (over night). Store the second flask with the 100 ml TH-media also in the 37 °C 
room (label the flask as described). Put the stock with bacteria back in the -70°C. 
6 Clean Eye gloom in flame again and clean the bench with 70 % alcohol.  
 
B next day: Expansion of the  Bakteria: 6h 
1 Take the bacteria suspension (50 ml TH-media which is now unclear) and the fresh 100 ml 
TH-media from the 37 °C room and put it into the ML-II lab.  
Clean the bench like described before.  
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Take 1 ml of the bacterial suspension (sterile with Gilson-pipette) and transfer it into the 100 
ml TH-media. Close the lid and put it to the 37 °C room. Open the lid slightly there.  
2 Grow the culture for 6 hours at 37 °C.  
3 Clean the banch like described. Dispose 50 ml of TH-media. 
  
C measuring of the OD, dilute the inoculum, exposing  
1 Turn on the Spectrophotometer 3P, prewarm (20-30 minutes), adjust to 620nm and single 
measurement. 
2 Clean the bench. Take the bacteria to the ML-II room.  
 Shake the bacteria suspension slightly (this is for a homogeneous distribution of the bacteria). 
 Take 1 ml (sterile) and add in to a cuvette. Take the second cuvette and fill it with water as 
blank.  
3 Place the cuvettes in the photometer. Determine zero by measuring the blank first.  
 Measure then the bacteria, OD should be between 0,8 and 0,9 ideally.  
4 In the case that OD is only 0,7 it is necessary to put he TH-media again to 37°C for 
approximately 20 minutes. Repeat this process twice or three times. 
 When OD has reached the optimal amount, continue with step 5.  
5 take the 100 ml of bacterial suspension and put it to two 50 ml Greiner Tubes (each tube 50 
ml), centrifuge at 4000rpm, 15 min, 4°C 
6 Discard supernatant slightly (pellet is soft and liquid) 
 Add in sterile NaCl to have a final volume of 50 ml. Centrifuge like described in step 5. 
7 Discard supernatant and collect the pellets in one tube.  
Add in again 50 ml NaCl and centrifuge again.  
8 Discard supernatant and add in 10 ml sterile NaCl (bacteria stock) 
9 produce dilutions: in two Steps: 1:1000 dilution: 
   A. 1: 20 dilution:  1ml bacteria stock  
      19ml NaCl 
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   B 1: 50 dilution:  1ml of A 
      49ml NaCl 
10 it depends on the value of OD (if OD is higher than 0,9) dilute additionaly 1:5 (1ml von B + 4ml 
NaCl) 
11 final dilution (either 9B or 10) put on ice. 
This final bacteria suspension is needed for 1. the mice and  
2. has to be exposed to Bloodagar plates, to determine the real concentration of bacteria.   
12 Determination of the bacterial density: 5 small tubes (Micronic) with 180 µl of sterile NaCl 
each, label 1 to 5. Add in 20 µl of the bacterial suspension (that means 9 B or 10) in tube # 1, 
mix it properly. Abolish the pipette tip and take a new one. Add in 20µl of the solution in tube 
#1 to tube # 2, mix it properly, and continue with this procedure till tube #5. 
13 take 7 Bloodagar plates and label them with date, name and dilutionfactor: make the following 
dilutions: undiluted, 2x 10-3, 2x 10-4 und 2x10-5. Take 50 µl of the undiluted solution (from 9 B 
or 10) and pipette it on the plate and dispense it over the plate with a sterile glass scoop. Take 
50 µl of tube #3 and pipette it on both of the two plates and proceed in the same way. 
 Continue with this processing for the remaining plates. 
 Put the plates in the 37°C room (with the lid down). 
 Count CFUs the next day and write down the number. 
D Disposal of the bacteria and solutions  
1 The remaining bacteria supspension as well as the supernatant have to be put to a glasbottle 
and pooled. When the work is finished it is necessary to autoclave (20 minutes, 120°C) and 
dispose as liquid labwaste.  
2 Put the bloodagar plates after the counting in a blue Meteka-bag. 
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Protocol for heat shock transformation of E. coli 
 
1) competent cells were defrosted on ice and the plasmid DNA was added (50ng is sufficient, as 
a control PUC19 was used) 
2) incubation on ice for 30min, heat shock at 42°C for 45sec, again ice for 2min 
3) added 200 – 300µl SOC media (or LB) and incubated for 1h on a shaker 
4) bacteria were plated out on LB-agar (supplemented with the appropriate antibiotics) and 
incubated over night at 37°C 
 
 
 
Protocol for heat inactivated bacteria 
Molecular biology methods, SOP#8, Version01 
Autor: Karin Stich, Tanja Furtner 
Approved: Sylvia Knapp 
 
Materials 
Buffers: 
LB-Medium: 1% Tryptone (Sigma T9410); 0,5% Yeast Extract (Sigma Y0375); 1% NaCl (Merck 
1.06404) in A.dest. 
Additionally required reagents, disposables and devices:  
A.dest. (Mayrhofer Pharmazeutika; 15.533) 
0,9% NaCl solution (Mayerhofer Pharmazeutika; 15.553) 
Columbia blood agar plates (Bio Merieux; 43041) 
Latex gloves DermaClean®  (Ansell; PFC4303971/30001); required for the whole procedure!!! 
Needle, sterilized by flame (Lab VI) 
sterilized Glassware, several 
Gilson Pipetman P20 
Gilson Pipetman P100 
Gilson Pipetman P1000 
1-20µl  Bevelled Filter Tip (StarLab; S1120-1810) 
1-100µl Bevelled Filter Tip (StarLab; S1120-1840) 
101-1000µl Filter Tips (StarLab; S1126-7810) 
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10ml Stripette® (Costar®; 4101) 
Pipetboy accu, Integra Biosciences 
15ml  PP tubes Cellstar® (Greiner ; 188-261) 
1,5ml Mixed Colors Flat Cap Microcentrifuge Tubes „epi“ (StarLab; S1615-5599) 
Cuvettes; greiner bio-one (nr.613101) 
Centrifuge Rotanta 460R; Hettich 
Vortex  
Balance METTLER PJ3000, use for 0,01-1000g 
Spectrophotometer U-2000; Hitachi 
 
Working Procedure  
• inoculate bacteria of interest on a blood agar plate and strike to the colony (see classical 
microbiological literature) 
• incubate over night at 37°C 
• put 20ml LB in a 100ml Glass Erlenmeyer flask 
• take 6 single colonies with a sterile needle and inoculate 20ml LB-Medium 
• incubate 1,5-2,5h/37°C/200rpm 
• take 1ml and measure OD at 620nm (take water for blank) 
• if OD ~1 put 9ml in a 15ml Falcon tube and centrifuge 4°C/4000rpm/12min (if not grow until 
OD~1) 
• discard supernatant and resuspend pellet in 10ml NaCl solution 
• centrifuge again 4°C /4000rpm/12min 
• repeat centrifugation step 
• do colony count → see SOP#15 
• heat inactivate remaining suspension in a waterbath at 65°C/30min 
• store heat inactivated solution at -20°C 
For non fastidious bacteria (as Streptococcus pneumoniae and Haemophilus influenzae) please refer 
to classical bacteriological literature for changes in working procedure (especially growing media and 
circumstances) 
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Protocol for FITC labeling heat killed bacteria 
 
1) prepare fresh 0.1M NaHCO3 at pH 9.0 (adjusted with NaOH) 
2) thaw heat killed bacteria (stored in 50ml falcon at -20°C) 
3) spin down: 2800rpm, 8min, spill supernatant 
4) add 10ml 0.1M NaHCO3 to the pellet 
5) spin down again 
6) meanwhile dissolve 4mg of FITC (Sigma, F7250) in 1ml 0.1M NaHCO3 and filter solution 
through a fine mesh (FACS tubes with blue filter) 
7) dilute FITC solution to a concentration of 0.2mg/ml with 0.1M NaHCO3 
8) resuspend bacteria in all the 20ml of FITC solution 
9) incubate for 1h at 37°C in shaking water bath 
10) spin down and trash supernatant 
11) wash 1x with PBS and spin again 
12) resuspend to get a final concentration of 10E9 CFU/ml and aliquot in to 2ml tubes (1ml per 
tube) 
 
